thiazoles has been researched along with Schizophrenia in 448 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (3.13) | 18.2507 |
| 2000's | 227 (50.67) | 29.6817 |
| 2010's | 191 (42.63) | 24.3611 |
| 2020's | 16 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Guan, X; Kosten, TR; Liu, J; Wang, Y; Wu, F; Xiu, M; Zhang, X; Zhu, C | 1 |
| Chan, HY; Chen, JJ; Lin, CH; Lin, HY; Lin, TC | 1 |
| Bai, L; Guo, Y; Li, J; Li, K; Li, Y; Liang, W; Liu, L; Liu, Z; Wang, J; Wang, X; Wu, Y; Xu, J; Yang, F; Yu, J; Zhang, C; Zhang, Y | 1 |
| Horikoshi, S; Ichinose, M; Miura, I; Suzuki, Y; Watanabe, K | 1 |
| Crippa, A; Davis, JM; Leucht, S; Orsini, N; Patel, MX; Siafis, S | 1 |
| Broder, MS; Chang, E; Greene, M; Houle, CR; Tarbox, MH; Waters, HC; Yan, T | 1 |
| Ayesa-Arriola, R; Crespo-Facorro, B; Gómez-Revuelta, M; Juncal-Ruiz, M; Pelayo-Terán, JM; Romero-Jiménez, R; Setién Suero, E; Suárez-Pinilla, P; Vázquez-Bourgon, J | 1 |
| Madden, K; Mahgoub, Y; Xia, T | 1 |
| Correll, CU; DiPetrillo, L; Jiang, Y; Liu, Y; Pathak, S; Todtenkopf, MS | 1 |
| Chen, Q; Coid, J; Deng, W; Guo, W; Hu, X; Li, K; Li, L; Li, T; Li, X; Li, Y; Lu, T; Lv, L; Ma, X; Ren, H; Reynolds, GP; Tan, L; Tan, Q; Tian, Y; Wang, C; Wang, H; Wang, L; Wang, Q; Wei, W; Yan, H; Yang, F; Yang, G; Yang, J; Yu, H; Yue, W; Zhang, D; Zhang, F; Zhang, H; Zhang, Y; Zhao, L | 1 |
| Buchmann, J; Dück, A; Grözinger, M; Häßler, F; Hofmockel, R; Höppner, J; Reinhardt, M; Weirich, S | 1 |
| Ahmad, FJ; Ahmed, MZ; Hasan, N; Jain, GK; Khan, UA; Parveen, U; Saad, S | 1 |
| Claro, A; Corte-Real, F; Franco, J; Monteiro, C; Mustra, C; Proença, P | 1 |
| Ayesa Arriola, R; Crespo Facorro, B; Gómez Revuelta, M; Ibáñez Alario, M; Juncal Ruiz, M; Mayoral-van Son, J; Ortiz-García de la Foz, V; Vázquez-Bourgon, J | 1 |
| Harvey, PD; Loebel, A; Miller, BJ; Newcomer, JW; Pikalov, A; Siu, CO; Tocco, M; Tsai, J | 1 |
| Broadbent, M; Dobson, RJB; Dzahini, O; Govind, R; Ibrahim, ZM; Iqbal, E; Kim, CH; MacCabe, JH; Romero, A; Smith, T; Stewart, R; Werbeloff, N | 1 |
| Barber, S; Cipriani, A; Corsi, M; Olotu, U | 1 |
| Crespo-Facorro, B; Gomez-Arnau, J; Juncal-Ruiz, M; Martinez-Garcia, O; Neergaard, KD; Ortiz-Garcia de la Foz, V; Ramirez-Bonilla, M; Suarez-Pinilla, P; Tabares-Seisdedos, R | 1 |
| Cao, D; Kang, B; Meng, Y; Ning, H; Wang, H; Xie, S | 1 |
| Kou, C; Liu, X; Liu, Y; Ma, Y; Song, Y; Su, Y; Wang, M; Yang, G; You, Y; Zhang, L; Zhang, Y | 1 |
| Siegfried, N; Stein, DJ; Temmingh, HS; Williams, T | 1 |
| Bian, X; Huang, X; Huang, Z; Jiao, W; Li, Y; Luo, L; Meng, Y; Sun, L; Sun, Q; Tang, J; Wang, K; Wang, X; Yang, T; Zhang, F | 1 |
| Bogers, JPAM; Broekman, TG; de Haan, L; Moleman, P; Schulte, PFJ | 1 |
| Crespo-Facorro, B; Gómez-Revuelta, M; González-Pinto, A; Juncal-Ruiz, M; Ortiz-García de la Foz, V; Pelayo-Terán, JM; Vázquez-Bourgon, J | 1 |
| Bottlender, R; Jäger, M; Laux, G; Möller, HJ; Musil, R; Obermeier, M; Riedel, M; Schennach, R; Schmauss, M; Spellmann, I | 1 |
| Gao, Q; Jiao, WX; Lu, W; Miao, YZ; Sun, LL; Sun, Q; Wang, K; Wang, XT; Wei, NN; Yang, TY; Zhou, QQ | 1 |
| Bellavia, A; Centorrino, F; Fitzmaurice, G; Jackson, JW; Valeri, L | 1 |
| Adams, CE; Kwong, JS; Nyakyoma, K; Qi, F; Sinclair, DJ; Zhao, S | 1 |
| Cucchiaro, J; Hsu, C; Kalali, AH; Loebel, A; Pikalov, A; Potkin, SG; Sarma, K; Xu, L | 1 |
| Borlido, C; Caravaggio, F; Deluca, V; Graff-Guerrero, A; Ismail, Z; Mamo, D; Mulsant, B; Pollock, B; Remington, G; Suzuki, T; Uchida, H | 1 |
| Cucchiaro, J; Hsu, J; Loebel, A; Nasrallah, HA; Phillips, D; Silva, R; Xu, J | 1 |
| Crespo-Facorro, B; Martínez-Garcia, O; Mata, I; Ortiz-Garcia de la Foz, V; Pérez-Iglesias, R; Valdizan, EM; Vazquez-Barquero, JL | 1 |
| Deng, H; Gao, C; Karayal, ON; Li, K; Pan, S; Shi, J; Shu, L; Tang, H; Vanderburg, D; Wang, G; Wang, X; Xie, S; Xu, X; Zhang, H; Zhao, J | 1 |
| Higuchi, Y; Ito, T; Sumiyoshi, T; Suzuki, M | 1 |
| El-Sayeh, HG; Hunger, H; Khanna, P; Komossa, K; Leucht, S; Rummel-Kluge, C; Schwarz, S | 1 |
| Citrome, L; Cucchiaro, J; Hernandez, D; Hsu, J; Loebel, A; McEvoy, JP; Pikalov, A | 1 |
| Suzuki, M; Takahashi, S; Uchiyama, M | 1 |
| Arnold, JG; Cañive, JM; Miller, AL; Mintz, J; Rosenheck, RA; Swartz, MS | 1 |
| Cucchiaro, J; Hsu, J; Loebel, A; Pikalov, A; Simonelli, D; Stahl, SM | 1 |
| Amrutheshwar, R; Dkhar, SA; George, M; Kattimani, S; Rajkumar, RP | 1 |
| Cucchiaro, J; Kane, JM; Loebel, A; Pikalov, A; Sarma, K; Xu, J | 1 |
| Bruni, C | 1 |
| Calabrese, JR; Gao, K; Karayal, ON; Kolluri, S; Pappadopulos, E | 1 |
| Chen, H; Fang, M; Ou, J; Shao, P; Wu, R; Xu, Y; Zhao, J | 1 |
| Rossi, A; Stratta, P | 1 |
| Grossman, F; Hassan, M; Meyer, K; O'Day, K; Rajagopalan, K | 1 |
| Bies, RR; Graff-Guerrero, A; Mamo, DC; Mimura, M; Pollock, BG; Suzuki, T; Tsuboi, T; Uchida, H | 1 |
| Loebel, A; Meyer, K; O'Day, K; Pikalov, A; Rajagopalan, K | 1 |
| Achtyes, ED; Buckley, P; Bustillo, JR; Citrome, L; Gil, R; Goff, DC; Macklin, EA; Manschreck, TC; McEvoy, JP; Mech, AW | 1 |
| Iwata, N; Kishi, T | 1 |
| Riva, MA; Tarazi, FI | 1 |
| Hong, JP; Kim, MS; Park, S; Yi, KK | 1 |
| Li, CH; Rao, SZ; Shi, L; Zhan, GL; Zhang, H | 1 |
| Bies, RR; Mamo, DC; Mimura, M; Moriguchi, S; Pollock, BG; Remington, G; Suzuki, T; Uchida, H; Watanabe, K | 1 |
| Bobes García, J; de la Gándara Martín, JJ; Gutiérrez Fraile, M | 1 |
| Chiu, YY; Ereshefsky, L; Loebel, A; Poola, N; Preskorn, S | 1 |
| Cucchiaro, J; Harvey, PD; Hsu, J; Loebel, A; Maruff, P; Siu, CO | 1 |
| Keator, DB; Kesler-West, ML; Mukherjee, J; Nguyen, DD; Potkin, SG; Preda, A; Shah, N; van Erp, TG | 1 |
| Hugdahl, K; Johnsen, E; Jørgensen, HA; Kroken, RA; Løberg, EM; Sinkeviciute, I | 1 |
| Cavuş, I; DelBello, MP; Findling, RL; Gundapaneni, BK; Pappadopulos, E; Schwartz, JH; Vanderburg, DG | 1 |
| Koplewicz, HS | 1 |
| Abenavoli, E; Bruno, A; Lamberti Castronuovo, E; Micò, U; Muscatello, MR; Pandolfo, G; Scimeca, G; Spina, E; Zoccali, R | 1 |
| Asmal, L; Flegar, SJ; Komossa, K; Leucht, S; Rummel-Kluge, C; Wang, J | 1 |
| Citrome, L; Czobor, P; Van Dorn, RA; Volavka, J | 1 |
| Cucchiaro, JB; Harvey, PD; Loebel, AD; Pikalov, AA; Siu, CO | 1 |
| Maehara, S | 1 |
| Lin, H; Rosenheck, R | 1 |
| Aida, SA; Hatim, A; Mohamed, Z; Reynolds, GP; Roffeei, SN; Said, MA; Zainal, NZ | 1 |
| Dai, G; Zhang, Y | 1 |
| Iwata, N; Kishi, T; Matsuda, Y | 1 |
| Awad, G; Hassan, M; Hsu, J; Loebel, A; Pikalov, A; Rajagopalan, K | 1 |
| Chue, P; Mandel, FS; Therrien, F | 1 |
| Eng, SM; Fleischhacker, WW; Geier, J; Kane, JM; Karayal, O; Kolluri, S; Reynolds, RF; Strom, BL | 1 |
| Aguglia, E; Bianchini, O; Cannavò, D; De Ronchi, D; Nespeca, C; Porcelli, S; Serretti, A; Trappoli, A | 1 |
| Li, Y; Liu, X; Sun, F; Teng, L; Wang, D; Zhao, J; Zhou, Y | 1 |
| Jiang, Y; McGinnis, JJ; Ni, W | 1 |
| Choi, SH; Jung, BJ; Jung, WY; Kang, DH; Kim, SG; Lee, JS; Lee, YM; Shin, DH | 1 |
| Cucchiaro, JB; Loebel, AD; Mao, Y; Nasrallah, HA; Pikalov, AA | 1 |
| Kuntz, KM; Park, T | 1 |
| Albers, LJ; Conca, A; Mandrioli, R; Mercolini, L; Protti, M; Raggi, MA | 1 |
| Balaban, E; Cwikel-Hamzany, S; Fostick, L; Juven-Wetzler, A; Zohar, J | 1 |
| Buckley, PF | 1 |
| Ikeda, K; Murai, T; Nakamichi, K; Shimizu, I | 1 |
| Brennan, MD; Ramsey, TL | 1 |
| Ben Gharbia, M; Garnier, M; Llorca, PM; Samalin, L | 1 |
| Mandrioli, R; Mercolini, L; Protti, M | 1 |
| Crespo-Facorro, B; Prieto, C; Sainz, J | 1 |
| Caravaggio, F; Chung, JK; Fervaha, G; Gerretsen, P; Graff-Guerrero, A; Iwata, Y; Mihashi, Y; Mulsant, B; Nakajima, S; Plitman, E; Remington, G; Takeuchi, H | 1 |
| Calabrese, JR; Carta, MG; Moro, MF; Nardi, AE | 1 |
| Geerts, H; Potkin, S; Roberts, P; Spiros, A | 1 |
| Fabbri, C; Kato, M; Kinoshita, T; Koshikawa, Y; Nonen, S; Okugawa, G; Sakai, S; Serretti, A; Sunada, N; Takekita, Y; Wakeno, M | 3 |
| Iskandar, JW; Kablinger, A; Kavuru, B; Vance, JE | 1 |
| Lin, H; McEvoy, J; Mohamed, S; Rosenheck, RA; Stroup, S; Swartz, M | 1 |
| Fleischhacker, WW; Karayal, ON; Kemmler, G; Kolluri, S; Vanderburg, D; Widschwendter, CG | 1 |
| Eddings, W; Franklin, JM; Kesselheim, AS; Landon, J; Wang, B | 1 |
| Alonso-Martín, C; Arias-Loste, MT; Crespo, J; Crespo-Facorro, B; Fábrega, E; Martínez-García, O; Morlán-Coarasa, MJ; Ortiz-García de la Foz, V; Romero-Gómez, M | 1 |
| Álvarez-García, R; Baca-García, E; Barrigón, ML; Berrouiguet, S; Brandt, SA; Carballo, JJ; Courtet, P; Lenca, P; Ovejero-García, S | 1 |
| Bai, YH; Cai, M; Chen, YC; Guo, L; McAlonan, GM; Tan, QR; Wang, HH; Wang, HN; Wang, Y; Wu, WJ; Zhang, RG; Zhang, YH; Zhang, ZJ | 1 |
| Loebel, A; Meyer, N; Rajagopalan, K; Wade, S | 1 |
| Bentaleb, LA; Cherbal, A; Luck, D; Lungu, O; Stip, E; Zhornitsky, S | 1 |
| Hamilton, J; Heaton, C; Lannan, R; Lavedan, C; Licamele, L; Mack, K; Polymeropoulos, MH; Thompson, A; Volpi, S; Wolfgang, CD | 1 |
| Hamilton, JB; Heaton, C; Lannan, R; Lavedan, C; Licamele, L; Mack, K; Polymeropoulos, MH; Volpi, S; Wolfgang, CD | 1 |
| Sikich, L | 1 |
| Daumit, GL; Davis, SM; Davis, VG; Goff, DC; Hsiao, J; Lieberman, JA; McEvoy, JP; Meyer, JM; Nasrallah, HA; Stroup, TS; Swartz, MS | 1 |
| Romeo, F; Rossi, A; Tiradritti, P; Vita, A | 1 |
| Dressing, H; Krumm, B; Kuwilsky, A; Zink, M | 1 |
| Fusar-Poli, RR | 1 |
| Chen, CK; Chen, HK; Tzeng, NS | 1 |
| Alvarez, Jdo N; Carvalho, Rde C; Frussa-Filho, R; Fukushiro, DF; Ribeiro, LT; Ricardo, VP | 1 |
| Montejo, AL; Rico-Villademoros, F | 1 |
| Haug, HJ; Kolb, SA; Koponen, H; Lublin, H; Sigmundsson, T | 1 |
| DelBello, MP; Ice, K; Keller, D; Miceli, J; Versavel, M | 1 |
| Loebel, A; O'Gorman, CJ; Simpson, GM; Yang, R | 1 |
| Bartenstein, P; Boy, C; Bröcheler, A; Buchholz, HG; Cumming, P; Fellows, C; Gründer, G; Hiemke, C; Janouschek, H; Landvogt, C; Rösch, F; Schäfer, W; Spreckelmeyer, K; Vernaleken, I; Veselinovic, T; Wong, DF | 1 |
| Kang, SG; Kim, H; Lee, HJ; Lee, KJ; Lee, SH; Park, YM | 1 |
| Alderman, JA; Gandelman, K; Glue, P; LaBadie, RR; Lombardo, I; Preskorn, SH; Versavel, M | 1 |
| Addington, DE; Johnson, G; Kulkarni, J; Labelle, A; Loebel, A; Mandel, FS | 1 |
| Harvey, PD; Kremer, CM; Lombardo, I; Pappadopulos, E | 1 |
| Blasey, C; Davis, JM; Kraemer, H; Lieberman, JA; Reaven, GM; Schatzberg, AF; Sethuraman, G; Tsuang, MT | 1 |
| Galluzzo, A; Gorini, B; Romeo, F; Sacchetti, E; Valsecchi, P; Warrington, L | 2 |
| Borba, CP; Boxill, R; Cather, C; Copeland, PM; Evins, AE; Fan, X; Forstbauer, SI; Freudenreich, O; Goff, DC; Henderson, DC; Miley, K; Sharma, B | 1 |
| Allison, DB; Giller, E; Loebel, A; Parsons, B; Romano, S; Siu, C; Williams, K | 1 |
| Ascher-Svanum, H; Ball, T; Conley, R; Liu, L; Stauffer, V | 1 |
| Díaz-Marsá, M; Rico-Villademoros, F; Sánchez, S | 1 |
| Citrome, L; Glue, P; Karayal, ON; Yang, R | 1 |
| Arai, H; Higuchi, Y; Itoh, T; Kawasaki, Y; Kurachi, M; Matsui, M; Sumiyoshi, C; Sumiyoshi, T; Suzuki, M | 1 |
| Loebel, AD; Potkin, SG; Siu, CO; Warrington, LE; Watsky, EJ; Weiden, PJ | 1 |
| Goldberg, TE; Gomar, JJ | 1 |
| Cucchiaro, J; Guarino, J; Loebel, A; Nakamura, M; Ogasa, M; Phillips, D; Severs, J | 1 |
| Akkaya, C; Alptekin, K; Brook, S; Danaci, AE; El Tallawy, H; Hafez, J; Karayal, ON; Lowe, W; Tzebelikos, E; Ucok, A | 1 |
| Buitelaar, JK; Grootens, KP; Kahn, RS; Peuskens, J; Sabbe, BG; Thys, E; van Veelen, NM; Verkes, RJ | 1 |
| Kato, M; Kinoshita, T; Kishimoto, T; Koh, J; Matsumoto, N; Morikawa, M; Okugawa, G; Shinosaki, K; Wakeno, M; Yoneda, H | 1 |
| Lavedan, C; Licamele, L; Malhotra, AK; Potkin, SG; Volpi, S | 1 |
| Barbui, C; Boso, M; Cipriani, A | 1 |
| Coskun, O; Dalkiran, M; Duran, A; Emul, M; Keles, I; Tosun, M; Ugur, M; Yavuz, R | 1 |
| Citrome, L; Jaffe, A; Levine, J | 1 |
| Citrome, L | 9 |
| Kuehn, BM | 1 |
| Camargos, ST; Cardoso, FE; Prais, HA; Viana, Bde M | 1 |
| Aberg, K; Adkins, DE; Lieberman, JA; McClay, JL; Perkins, DO; Stroup, S; Sullivan, PF; van den Oord, EJ; Vladimirov, VI | 1 |
| Loebel, AD; Meyer, JM; Schweizer, E | 1 |
| Dadić-Hero, E; Knez, R; Medved, P; Petrić, D; Ruzić, K | 1 |
| Bhoopathi, PS; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schwarz, S | 1 |
| Citrome, L; Cuffel, B; Harnett, J; Lenhart, G; Montejano, LB; Palmer, L; Reist, C; Sanders, KN | 1 |
| Herman, BK; Lawson, WB; Lazariciu, I; Loebel, A; Malik, M | 1 |
| DelBello, MP; Keller, D; Stewart, M; Versavel, M | 1 |
| Lavedan, C; Thompson, A; Volpi, S | 1 |
| Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S; Silveira da Mota Neto, JI | 1 |
| Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S; Srisurapanont, M | 1 |
| Anziano, R; Harrigan, RH; Miceli, JJ; O'Gorman, C; Shiovitz, T; Tensfeldt, TG | 1 |
| Burns, T; Derks, EM; Fleischhacker, WW; Gaebel, W; Kahn, RS; Riesbeck, M; Rössler, W; von Wilmsdorff, M | 1 |
| Duggan, L; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S | 1 |
| Peitl, MV; Peitl, V; Petrić, D | 1 |
| Benedetti, AM; Frazee, LA; Leung, JG; Myers, N | 1 |
| Arakawa, R; Ito, H; Okubo, Y; Okumura, M; Suhara, T; Takahashi, H; Takano, A; Takano, H | 1 |
| Fukui, N; Inoue, Y; Ono, S; Sawamura, K; Someya, T; Sugai, T; Suzuki, Y; Tsuneyama, N; Watanabe, J | 1 |
| Fujii, A; Furukori, H; Inoue, Y; Kaneko, S; Sugawara, N; Tsuchimine, S; Yasui-Furukori, N | 1 |
| Anziano, RJ; Harrigan, RH; Miceli, JJ; O'Gorman, C; Shiovitz, T; Tensfeldt, TG | 1 |
| Bacalis, S; Chatziioannou, S; Douzenis, A; Fotiadis, C; Katsantoni, E; Lykouras, L; Mandrapilia, A; Rizos, EN; Siafakas, N | 1 |
| Potvin, S; Stip, E; Tourjman, V; Zhornitsky, S | 1 |
| Grootens, KP; Kahn, RS; Peuskens, J; Sabbe, BG; Salden, ME; Sitskoorn, MM; van Veelen, NM; Verkes, RJ | 1 |
| Bae, KY; Kim, JM; Kim, SW; Shin, IS; Yang, SJ; Yoon, JS | 1 |
| Lincoln, J; Preskorn, SH; Stewart, ME | 1 |
| Harvey, PD; Loebel, A; Malla, A; Newcomer, JW; Potkin, SG; Romano, S; Siu, CO; Stahl, SM; Watsky, E; Weiden, PJ | 1 |
| Grignon, S; Roy-Desruisseaux, J | 1 |
| Cañas, F; Fagiolini, A; Gallhofer, B; Larmo, I; Levy, P; Montes, JM; Papageorgiou, G; Rossi, A; Zink, M | 1 |
| Davis, JM; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Lobos, CA; Rummel-Kluge, C; Schmid, F; Schwarz, S | 1 |
| Campbell, EC; Caroff, SN; Chakos, MH; Davis, SM; Davis, VG; Keefe, RS; Lieberman, JA; McEvoy, JP; Miller, DD; Riggio, S; Rosenheck, RA; Saltz, BL; Stroup, TS; Swartz, MS | 1 |
| Buitelaar, JK; Grootens, KP; Kahn, RS; Peuskens, J; Sabbe, BG; Sitskoorn, MM; van Veelen, NM; Verkes, RJ | 1 |
| Hori, H; Nakamura, J; Okamoto, T; Umene-Nakano, W; Yoshimura, R | 1 |
| D'Agostino, RB; Eng, SM; Faich, G; Kane, JM; Reynolds, RF; Ruskin, J; Strom, BL | 1 |
| Gen, K; Inoue, Y; Suzuki, H | 1 |
| Asenjo Lobos, C; Hunger, H; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S | 1 |
| Cucchiaro, J; Fox, KH; Harvey, PD; Keefe, RS; Loebel, A; Siu, C | 1 |
| Case, M; Conley, RR; Hoffmann, VP; Jacobson, JG; Stauffer, VL | 1 |
| Abi-Dargham, A; Cangiano, C; Frankle, WG; Gil, R; Huang, Y; Hwang, DR; Kegeles, LS; Laruelle, M; Lombardo, I; Martin, JH; Reich, E; Slifstein, M | 1 |
| Celikyurt, IK; Erden, FB; Kayir, H; Ulak, G; Ulusoy, GK; Uzbay, TI | 1 |
| Mandel, FS; Masand, P; O'Gorman, C | 1 |
| Bies, RR; Coley, K; Kirshner, MM; Li, CH; Lieberman, JA; Marder, SR; Pollock, BG; Schneider, LS; Stroup, S; Wessels, AM | 1 |
| Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S | 1 |
| Cucchiaro, J; Harvey, PD; Keefe, RS; Loebel, A; Ogasa, M | 1 |
| Cañas, F; Correll, CU; Fagiolini, A; Larmo, I; Levy, P; Montes, JM; Papageorgiou, G; Rossi, A; Sturlason, R; Zink, M | 1 |
| Stroup, TS | 1 |
| Bobo, WV; Crystal, S; Gerhard, T; Huang, C; Lieberman, JA; Olfson, M | 1 |
| Bachinsky, M; Cavus, I; Chappell, P; Glue, P; Karayal, ON; Kolluri, S; Stewart, M | 1 |
| Montes, JM | 1 |
| Howland, RH | 1 |
| Dadić-Hero, E; Grahovac, T; Palijan, TZ; Petranović, D; Ružić, K; Sepić-Grahovac, D | 1 |
| Anway, SD; Batzar, E; Karayal, ON; Vanderburg, DG | 1 |
| Hasnain, M; Vieweg, WV | 1 |
| Cucchiaro, J; Kalali, AH; Loebel, A; Meltzer, HY; Ogasa, M; Phillips, D; Pikalov, A; Schweizer, E; Silva, R; Xu, J | 1 |
| Mautone, A; Scarone, S | 1 |
| Camm, JA; Eng, S; Geier, JL; Karayal, ON; Keane, M; Kolluri, S; Kremer, CM; Lewis, M; Reynolds, R; Strom, BL | 1 |
| Alvir, JM; Crabtree, BL; Cuffel, BJ; Dostrow, VG; Evans, CJ; Sanders, KN | 1 |
| Bitter, I; Czobor, P; Derks, EM; Fleischhacker, WW; Kahn, RS; Libiger, J; Volavka, J | 1 |
| Cucchiaro, J; Loebel, A; Ogasa, M; Potkin, SG | 1 |
| Jakovljevic, M; Mihaljevic-Peles, A; Muck-Seler, D; Mustapic, M; Nedic, G; Nikolac, M; Pivac, N; Sagud, M; Vuksan Cusa, B | 1 |
| Horiguchi, M; Li, X; Meltzer, HY; Wei, J; Yan, Z; Yuen, EY | 1 |
| Lerner, V; Miodownik, C; Witztum, E | 1 |
| Owen, RT | 1 |
| Citrome, L; Hochfeld, M; Meng, X; Stahl, SM | 1 |
| Dudova, I; Hrdlicka, M; Urbanek, T; Zedkova, I | 1 |
| Kaushik, S; Khan, A; Lindenmayer, JP; Parakadavil, M; Smith, RC; Tedeschi, F; Yusim, A | 1 |
| Kane, JM | 4 |
| Berkowitz, RL; Docherty, JP; Ni, Q; Parks, JJ; Patel, U | 1 |
| Bobo, WV; Chen, Y; Jayathilake, K; Meltzer, HY; Tang, T; Watts, K | 1 |
| Ascher-Svanum, H; Bruhn, D; Graham, CN; Lawson, AH; Mauskopf, JA | 1 |
| Li, YM; Ou, JJ; Wu, RR; Zhao, JP | 1 |
| Bies, RR; Keefe, RS; Mamo, DC; Mimura, M; Pollock, BG; Rajji, TK; Sakurai, H; Stroup, ST; Suzuki, T; Uchida, H; Watanabe, K | 1 |
| Citrome, L; Kantrowitz, JT | 1 |
| Citrome, L; Cucchiaro, J; Loebel, A; Phillips, D; Sarma, K; Silva, R; Tsuchiya, S | 1 |
| Fukui, N; Ono, S; Saito, M; Someya, T; Sugai, T; Suzuki, Y; Tsuneyama, N; Watanabe, J | 1 |
| Hu, SH; Tao, J; Wang, JH; Wu, XL | 1 |
| Camm, AJ; Kane, JM; Karayal, ON; Kolluri, S; Meltzer, H; Miceli, J; O'Gorman, C; Tensfeldt, T | 1 |
| Nolan, SF; Roman, MW | 1 |
| Alsuwaidan, M; Cha, DS; Jerrell, JM; McIntosh, D; McIntyre, RS; Powell, AM | 1 |
| Sun, J; Xu, H; Zhao, Z | 1 |
| Mencacci, C | 1 |
| Fujiki, R; Matsuoka, T; Mori, K; Morita, K; Shoji, Y; Uchimura, N | 1 |
| Bitter, I; Bucci, P; Fleischhacker, WW; Galderisi, S; Kahn, RS; Libiger, J; Mucci, A | 1 |
| Yasui-Furukori, N | 1 |
| Adelekun, AE; Hannaway, KE; Horiguchi, M; Jayathilake, K; Meltzer, HY | 1 |
| Hopkins, CR | 1 |
| Danysz, W; Gyertyán, I; Jatzke, C; Kassai, F; Kedves, R; Lendvai, B; Pietraszek, M; Schlumberger, C | 1 |
| Kolluri, S; Newcomer, JW; Pappadopulos, E | 1 |
| Cho, YM; Jeong, SW; Jung, H; Kim, JH; Kwak, SN; Kwon, OJ; Lee, KW; Oh, JE | 1 |
| Stahl, SM; Tarazi, FI | 1 |
| Sumiyoshi, T | 1 |
| Alvir, JM; Berger, A; Edelsberg, J; Mychaskiw, MA; Oster, G; Sanders, KN | 1 |
| Correll, CU; De Hert, M; Detraux, J; Sweers, K; van Winkel, R; Yu, W | 1 |
| Guarino, J; Kimura, T; Nakamura, M; Ogasa, M | 1 |
| Moteshafi, H; Stip, E | 1 |
| Chen, HH; Fan, X; Gao, K; Guo, XF; Ou, JJ; Wang, J; Wu, RR; Xu, Y; Zhao, JP | 1 |
| Alvarez, E; Arranz, B; Corripio, I; Dueñas, R; Perez, V; Ramirez, N; Safont, G; San, L | 1 |
| Kato, M; Kinoshita, T; Nishida, K; Okugawa, G; Sakai, S; Suwa, A; Takekita, Y; Wakeno, M | 1 |
| Agid, O; Pappadopulos, E; Remington, G; Siu, CO; Vanderburg, D | 1 |
| Eng, SM; Faich, G; Kane, JM; Kolitsopoulos, FM; Reynolds, RF; Strom, BL | 1 |
| Buchmann, J; Häßler, F; Höppner, J; Pohl, B; Reis, O; Weirich, S | 1 |
| Sanford, M | 1 |
| Bobo, WV | 1 |
| Piazzi, G; Sciarretta, A | 1 |
| Cutler, AJ; Kalali, AH; Kunovac, J; Mattingly, GW; Meng, X | 1 |
| Gunasekara, NS; Keating, GM; Spencer, CM | 2 |
| Mack, JE; Reeves, RR | 1 |
| Arato, M; Meltzer, HY; O'Connor, R | 1 |
| Jessen, LM | 1 |
| Bellnier, TJ | 1 |
| Kimble, R; Reeves, RR | 1 |
| Kaye, NS | 1 |
| Iseki, E; Kase, A; Katsuse, O; Kosaka, K; Oyama, I; Shoji, M; Togo, T; Uchikado, H | 1 |
| Taylor, D | 1 |
| Nolan, BP; Schulte, JJ | 1 |
| O'Sullivan, RL; Potkin, SG; Simpson, GM; Weiden, PJ | 1 |
| Woods, SW | 1 |
| Jensen, PN; Stenstrøm, AD | 1 |
| Nishikawa, T; Takeuchi, T | 1 |
| Hauser, A; Larson, MF | 1 |
| Lieberman, JA; Stroup, TS | 1 |
| Harvey, PD; Romano, S; Siu, CO | 1 |
| Daniel, DG; Romano, SJ; Simpson, G; Weiden, PJ | 1 |
| Kropp, S; Schomerus, G; Ziegenbein, M | 1 |
| Chaki, S; Hirota, S; Kawashima, N; Okuyama, S | 1 |
| Honma, H; Iwasaki, S; Kondo, C; Masui, T; Matsubara, S; Osawa, T | 1 |
| Tamminga, CA | 1 |
| Shayegan, DK; Stahl, SM | 2 |
| Brook, S | 1 |
| Schooler, NR | 1 |
| Harvey, PD | 1 |
| Daniel, DG | 1 |
| Mandrioli, R; Pucci, V; Raggi, MA; Sabbioni, C | 1 |
| Buckley, PF; Glazer, W; Sebastian, CS | 1 |
| Berardi, D; De Ronchi, D; Lorenzi, C; Serretti, A | 1 |
| Kawai, M; Minabe, Y; Mori, N; Takei, N; Tani, K; Yokoshima, T | 1 |
| Bitter, I | 1 |
| Harvey, PD; Loebel, A; Meltzer, H; Potkin, SG; Romano, SJ; Simpson, GM; Siu, C | 1 |
| Lublin, HK | 1 |
| Nakamura, M; Nishida, M | 1 |
| Findling, RL; McNamara, NK | 1 |
| Loebel, A; Romano, S; Siu, C | 1 |
| Buchanan, RW; Buckley, PF; Chiles, JA; Conley, RR; Crismon, ML; Ereshefsky, L; Essock, SM; Finnerty, M; Hall, CS; Marder, SR; McEvoy, JP; Miller, A; Miller, DD; Rush, AJ; Saeed, SA; Schooler, NR; Shon, SP; Stroup, S; Tarin-Godoy, B | 1 |
| Kapur, S; Mamo, D; Mann, S; Papatheodorou, G; Remington, G; Shammi, CM; Therrien, F | 1 |
| Gaszner, G; Kosza, P | 1 |
| Assion, HJ; Schwenkreis, P | 1 |
| Dressing, H; Mase, E; Zink, M | 1 |
| Furukori, H; Inoue, Y; Kaneko, S; Nakagami, T; Saito, M; Tateishi, T; Yasui-Furukori, N | 1 |
| Andersen, MP; Hogg, S; Pouzet, B | 1 |
| Glick, ID; Romano, SJ; Simpson, GM; Siu, CO; Weiden, PJ | 1 |
| Mori, K; Morinobu, S; Nagao, M; Okamoto, Y; Yamashita, H; Yamawaki, S | 2 |
| Baldessarini, RJ; Berry, JM; Centorrino, F; Fogarty, KV; Kidwell, JE; MacLean, E; Salvatore, P | 1 |
| Byerly, M; Carmody, T; Holland, R; Li, B; Miller, DR; Montgomery, JH; Varghese, F | 1 |
| Addington, DE; Benattia, I; Dineen, M; Pantelis, C; Romano, SJ | 1 |
| Ananth, J; Burgoyne, KS; Niz, D; Smith, M | 1 |
| Benattia, I; Brook, S; Romano, SJ; Siu, CO; Walden, J | 1 |
| Abekawa, T; Kitaichi, Y; Koyama, T; Matsuyama, T | 1 |
| Brown, RR; Estoup, MW | 1 |
| Bowie, CR; Harvey, PD | 1 |
| Härtter, S; Hiemke, C; Sachse, J | 1 |
| Baldassano, C; Ballas, C; Ballas, P; O'Reardon, J; Yang, C | 1 |
| Cosi, C; Newman-Tancredi, A; Rollet, K; Tesori, V; Waget, A | 1 |
| Bartholomä, A; Gregor, A; Hein, J; Heinz, A; Juckel, G | 1 |
| Baker, TM; Matza, LS; Revicki, DA | 1 |
| Matsui-Sakata, A; Ohtani, H; Sawada, Y | 1 |
| Christensen, JD; Garver, DL; Holcomb, JA | 1 |
| Ross, DE | 1 |
| Carnahan, RM; Perry, PJ | 1 |
| Hwang, JP; Tsai, CF; Tsai, SJ | 1 |
| Murray, S; Pigott, T; Romano, SJ; Simpson, GM; Siu, CO; Weiden, P | 1 |
| Davis, CE; Davis, SM; Hsiao, JK; Keefe, RS; Lebowitz, BD; Lieberman, JA; McEvoy, JP; Perkins, DO; Rosenheck, RA; Severe, J; Stroup, TS; Swartz, MS | 1 |
| Berg, PH; Breier, A; Cavazzoni, P; Gattaz, WF; Kane, JM; Naber, D; Roychowdhury, SM; Thakore, JH; Walker, DJ | 1 |
| Araki, T; Iwanami, A; Kasai, K; Kato, N; Kuwabara, H; Suga, M; Sumiyoshi, T; Yamasue, H | 1 |
| Jayathilake, K; Meltzer, HY; Roy, A; Sumiyoshi, C; Sumiyoshi, T | 1 |
| Giller, E; Kane, JM; Khanna, S; Rajadhyaksha, S | 1 |
| Bozikas, VP; Fokas, K; Garyfallos, G; Giouzepas, J; Nikolaidis, N; Xomalis, D | 1 |
| Annable, L; Beauclair, L; Chouinard, G; Kolivakis, TT; Margolese, HC; Miller, R | 1 |
| Adams, DH; Kinon, BJ; Liu-Seifert, H | 1 |
| Daniel, DG; Harvey, PD; Kilts, CD; Lieberman, JA; Nemeroff, CB; Newcomer, JW; Schatzberg, AF; Weiden, PJ | 1 |
| Blow, FC; Dalack, GW; Ignacio, RV; McCarthy, JF; Stavenger, T; Valenstein, M | 1 |
| Luchins, DJ | 1 |
| Hsiao, JK; Lieberman, JA | 1 |
| Banks, SM; Pandiani, JA | 1 |
| Anghelescu, IG; Dettling, M | 1 |
| Bossie, CA; Canuso, CM; Gharabawi, GM; Greenspan, A; Lasser, RA; Mahmoud, R; Turkoz, I | 1 |
| Stone, AM | 1 |
| Bowie, CR; Harvey, PD; Loebel, A | 1 |
| Murray, S; Olié, JP; Spina, E; Yang, R | 1 |
| Canive, JM; Khan, A; Lieberman, JA; McEvoy, JP; McGee, M; Miller, DD; Reimherr, F; Rosenheck, RA; Stroup, TS; Swanson, JW; Swartz, MS; Van Dorn, R; Wagner, HR | 1 |
| Birinyi-Strachan, L; Davey, P; Kongsakon, R; Leelahanaj, T; Price, N | 1 |
| Carter, CT; Harrison, DJ; Joyce, AT; Loebel, AD; Ollendorf, DA | 1 |
| Harrison, DJ; Mullins, CD; Naradzay, J; Obeidat, N; Shaya, FT; Zito, JM | 1 |
| Davis, CE; Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Meltzer, HY; Perkins, DO; Rosenheck, RA; Severe, J; Stroup, TS; Swartz, MS | 1 |
| Davis, CE; Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Perkins, DO; Rosenheck, RA; Severe, J; Stroup, TS; Swartz, MS | 1 |
| Chou, YH; Ku, HL; Su, TP | 1 |
| Adams, DH; Ascher-Svanum, H; Edwards, SB; Kinon, BJ; Lipkovich, I; Siris, SG | 1 |
| Brook, S; Citrome, L; Czobor, P; Loebel, A; Mandel, FS; Volavka, J | 1 |
| Alvarez, E; Barrachina, J; Campins, MJ; Madre, M; Pascual, JC; Pérez, V; Soler, J | 1 |
| Araki, T; Iwanami, A; Kasai, K; Kato, N; Rogers, MA | 1 |
| Bowie, C; Green, MF; Harvey, PD; Loebel, A | 1 |
| Barak, Y; Baruch, Y; Mazeh, D; Plopski, I | 1 |
| Akkaya, C; Kirli, S; Kotan, Z; Sarandol, A; Sivrioglu, EY | 1 |
| Bates, JA; Burdick, KE; Kane, JM; Malhotra, AK; Razi, K; Sanders, M | 1 |
| Campbell, L; Cato, KJ; Clarke, K; Davies, CH; Gordon, L; Gribble, A; Heath, J; Jones, DN; Patel, N; Riley, G; Scott, C; Wood, MD; Worby, A | 1 |
| Bies, RR; Chew, ML; Gharabawi, G; Greenspan, A; Kapur, S; Kirshner, MA; Lehman, ME; Mulsant, BH; Pollock, BG | 1 |
| de Leon, J; Diaz, FJ; Markham-Abedi, C; McNeely, C; Villanueva, N | 1 |
| Gianfrancesco, FD; Rajagopalan, K; Sajatovic, M; Wang, RH | 1 |
| Baumgartner, S; Ebenbichler, C; Edlinger, M; Fleischhacker, WW; Hofer, A; Hummer, M; Kemmler, G; Lechleitner, M; Rettenbacher, MA | 1 |
| Naber, D; Phillips, GA; Roychowdhury, SM; Van Brunt, DL; Xu, W | 1 |
| Correll, CU; Frederickson, AM; Kane, JM; Manu, P | 1 |
| Aravagiri, M; Marder, SR; Pollock, B | 1 |
| Adams, DH; Citrome, L; Kinon, BJ; Liu-Seifert, H | 1 |
| Gil, R; Girgis, RR; Rosenfield, PJ | 1 |
| Balbo, E; Delgado, JF; Diez, T; Martin, E; Montes, JM; Rodriguez, JL; Sopelana, P; Soto, JA; Villardaga, I | 1 |
| Scott, LJ; Swainston Harrison, T | 1 |
| Domin, S; Kasper, S; Kudla, D; Lambert, M; Naber, D | 1 |
| Bernardo, M; Ramón Azanza, J; Rejas, J; Rubio-Terrés, C | 1 |
| De Oliveira, IR; Juruena, MF | 1 |
| Bartkó, G; Bitter, I; Degrell, I; Faludi, G; Füredi, J; Trixler, M | 1 |
| Asai, K; Shimada, Y; Tanaka, Y; Ueda, H; Yoshida, S | 1 |
| Hamanaka, S; Kamijo, Y | 1 |
| Ishii, E; Ishimatsu, S; Kizu, J; Otani, N; Tsuchiya, M | 1 |
| Capuano, G; Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; McGee, MF; Perkins, DO; Reimherr, F; Rosenheck, RA; Stroup, TS; Swartz, MS | 1 |
| Cansel, N; Herken, H; Ozen, ME; Savas, HA; Yumru, M | 1 |
| Arai, H; Higuchi, Y; Kurachi, M; Matsui, M; Meltzer, HY; Sumiyoshi, T; Takamiya, C | 1 |
| Aukst-Margetic, B; Margetic, B | 1 |
| Bowie, CR; Buckley, PF; Harvey, PD; Loebel, A | 1 |
| Colasanti, A; Dragogna, F; Fiorentini, A; Mauri, MC; Papa, P; Rossattini, M; Valli, A; Volonteri, LS | 1 |
| Bilder, RM; Capuano, G; Davis, CE; Davis, SM; Gold, JM; Green, MF; Harvey, PD; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Meltzer, HY; Palmer, BW; Perkins, DO; Rosenheck, RA; Stroup, TS; Swartz, MS | 1 |
| Goodman, C; Silver, H | 1 |
| Cuffel, BJ; Loebel, AD; Mullins, CD; Naradzay, J; Obeidat, NA | 1 |
| Citrome, L; Greenberg, WM | 1 |
| Gibel, A; Ratner, Y; Ritsner, MS; Soifer, P; Yorkov, V | 1 |
| Gibel, A; Ratner, Y; Ritsner, MS; Yorkov, V | 1 |
| Cañas, F; Díaz, S; Pérez-Solá, V; Rejas, J | 1 |
| Wooten, J | 1 |
| Chua, SE; Chung, AK | 1 |
| Giller, E; Khanna, S; Loebel, AD; Potkin, SG; Rajadhyaksha, S; Siu, CO | 1 |
| Loebel, A; Siu, C; Warrington, L; Yang, R; Zimbroff, D | 1 |
| Allen, MH; Nordstrom, K | 1 |
| Bick, P; Castle, D; Knoesen, N | 1 |
| Koyama, T; Kusumi, I; Masui, T | 1 |
| Neill, JC; Snigdha, S | 1 |
| de Leon, J; Markham-Abedi, C; McNeely, C | 1 |
| Bilder, RM; Galluzzo, A; Gorini, B; Harvey, PD; Loebel, AD; Romeo, F; Sacchetti, E | 1 |
| Calabrese, JR; Gajwani, P; Ganocy, SJ; Gao, K; Kemp, DE; Muzina, DJ | 1 |
| Alvarez, E; Pascual, JC; Pérez, V; Pérez-Egea, R; Puigdemont, D; Soler, J; Tiana, T | 1 |
| D'Agostino, RB; Eng, SM; Faich, GA; Kane, JM; Reynolds, RF; Ruskin, JN; Strom, BL | 1 |
| Cutler, AJ; Hamilton, J; Kalali, AH; Weiden, PJ; Wolfgang, CD | 1 |
| Boter, H; Davidson, M; Dollfus, S; Fleischhacker, WW; Gaebel, W; Galderisi, S; Gheorghe, MD; Grobbee, DE; Hranov, LG; Hummer, M; Kahn, RS; Keet, IP; Libiger, J; Lindefors, N; López-Ibor, JJ; Peuskens, J; Riecher-Rössler, A; Rybakowski, JK; Vergouwe, Y | 1 |
| Allingham, B; Citrome, L; Jaffe, A; Levine, J; Martello, D | 1 |
| Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Rosenheck, RA; Stroup, TS; Swartz, MS | 1 |
| Washburn, CF | 1 |
| Camacho-Ochoa, M; Evans, DL; Piercey, MF; Walker, EL | 1 |
| Benkert, O; Müller-Siecheneder, F; Wetzel, H | 1 |
| Lahti, AC; Tamminga, CA | 1 |
| Boncek, VM; Cooper, BR; Faison, WL; Howard, JL; Nanry, KP; Norman, MH; Pollard, GT; Rigdon, GC | 1 |
| Barnas, C; Heiden, A; Kasper, S; Laakmann, G; Pfolz, H; Volz, HP; Zeit, H | 1 |
| Goff, DC; Herz, L; Kletti, N; Ko, GN; Lapierre, K; Law, CG; Posever, T; Simmons, J; Wilner, KD | 1 |
| Buffenstein, A; Feighner, J; Ferguson, J; Harrigan, EP; Jaffe, W; Keck, P; Morrissey, MR | 1 |
| Daniel, DG; Harrigan, EP; Lakshminarayanan, M; Potkin, SG; Reeves, KR; Zimbroff, DL | 1 |
| Allison, DB; Cappelleri, JC; Chandler, LP; Cheskin, LJ; Fontaine, KR; Heo, M; Mentore, JL; Weiden, PJ | 1 |
| Chaki, S; Funakoshi, T; Kumagai, T; Nagamine, M; Nakazato, A; Okuyama, S; Tomisawa, K; Yoshikawa, R | 1 |
| Awad, AG; Voruganti, LN | 1 |
| Keck, PE; McElroy, SL; Strakowski, SM | 1 |
| Bagnall, A; Kleijnen, J; Leitner, ML; Lewis, RA | 1 |
| Möller, HJ | 1 |
| Bagnall, A; Leitner, ML; Lewis, RA | 1 |
| Copeland, LF; Daniel, DG | 1 |
| Ohno, Y | 1 |
| Kapur, S; Remington, G | 1 |
| Hilger, E; Kasper, S | 1 |
| Harrigan, EP; Lesem, MD; Reeves, KR; Swift, RH; Zajecka, JM | 1 |
| Casey, DE; Zorn, SH | 1 |
| Carnahan, RM; Lund, BC; Perry, PJ | 1 |
| Fayek, M; Kingsbury, SJ; Simpson, GM; Trufasiu, D; Zada, J | 1 |
| Hirsch, M | 1 |
| McClellan, K; Onrust, SV | 1 |
| Arnold, LM; Keck, PE; McElroy, SL | 1 |
| Sussman, N | 1 |
| Green, B | 1 |
| Gutierrez, MA; Lee, V; Stimmel, GL | 1 |
| Albert, MJ; Baldessarini, RJ; Centorrino, F; Kelleher, JP | 1 |
| Caley, CF; Cooper, CK | 1 |
| de Paulis, T | 1 |
| Bäuml, J; Hirsch, SR; Kissling, W; O'Connor, R; Power, A | 1 |
| Bregna, DE; Dunn, RW; Geyer, HM; Hartman, HB; Hrib, NJ; Jurcak, JG; Roehr, JE; Rogers, KL; Rush, DK; Szczepanik, AM | 1 |
105 review(s) available for thiazoles and Schizophrenia
| Article | Year |
|---|---|
Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy.
Topics: Antipsychotic Agents; Humans; Isoindoles; Lurasidone Hydrochloride; Schizophrenia; Serotonin; Thiazoles; Weight Gain | 2023 |
Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Topics: Acute Disease; Administration, Oral; Antipsychotic Agents; Aripiprazole; Clozapine; Delayed-Action Preparations; Dose-Response Relationship, Drug; Haloperidol; Humans; Imidazoles; Indoles; Isoxazoles; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Thiophenes | 2020 |
Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Clozapine; Dibenzothiazepines; Drug Resistance; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Piperazines; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Sulpiride; Thiazoles; Weight Gain | 2017 |
The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Humans; Insulin; Lurasidone Hydrochloride; Network Meta-Analysis; Olanzapine; Piperazines; Risperidone; Schizophrenia; Thiazoles | 2017 |
Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Diagnosis, Dual (Psychiatry); Humans; Mental Disorders; Olanzapine; Patient Dropouts; Perphenazine; Piperazines; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Substance-Related Disorders; Thiazoles | 2018 |
Electroconvulsive therapy for treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Electroconvulsive Therapy; Female; Flupenthixol; Humans; Male; Memory Disorders; Patient Readmission; Piperazines; Randomized Controlled Trials as Topic; Schizophrenia; Standard of Care; Thiazoles; Treatment Outcome | 2019 |
Aripiprazole versus other atypical antipsychotics for schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles | 2013 |
Newer antipsychotics and upcoming molecules for schizophrenia.
Topics: Antipsychotic Agents; Dibenzocycloheptenes; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Isoindoles; Isoxazoles; Lurasidone Hydrochloride; Piperazines; Piperidines; Schizophrenia; Thiazoles | 2013 |
Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophrenia.
Topics: Antipsychotic Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Piperazines; Randomized Controlled Trials as Topic; Schizophrenia; Sleep Stages; Thiazoles; Weight Gain | 2013 |
Efficacy and tolerability of perospirone in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Female; Humans; Isoindoles; Male; Middle Aged; Randomized Controlled Trials as Topic; Schizophrenia; Thiazoles; Young Adult | 2013 |
The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Depression; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Isoindoles; Lurasidone Hydrochloride; Schizophrenia; Thiazoles | 2013 |
Quetiapine versus other atypical antipsychotics for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Medication Adherence; Olanzapine; Piperazines; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles | 2013 |
[Pharmacological characterization of metabotropic glutamate-receptor 1 antagonist for the treatment of schizophrenia].
Topics: Animals; Benzimidazoles; Drug Discovery; Humans; Isoindoles; Mice; Molecular Targeted Therapy; Naphthalenes; Protein Binding; Rats; Receptors, Metabotropic Glutamate; Schizophrenia; Thiazoles; Triazoles | 2013 |
Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Double-Blind Method; Glycated Hemoglobin; Heart; Humans; Isoindoles; Piperazines; Piperidines; Randomized Controlled Trials as Topic; Risk; Schizophrenia; Thiazoles; Weight Gain | 2014 |
[Short-term efficacy and safety of lurasidone in the treatment of schizophrenia].
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Isoindoles; Lurasidone Hydrochloride; No-Observed-Adverse-Effect Level; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome | 2014 |
Evaluation of the pharmacokinetics, safety and clinical efficacy of ziprasidone for the treatment of schizophrenia and bipolar disorder.
Topics: Animals; Antipsychotic Agents; Bipolar Disorder; Disorders of Excessive Somnolence; Dizziness; Drug Evaluation; Humans; Piperazines; Schizophrenia; Thiazoles; Treatment Outcome | 2015 |
Potential use of lurasidone for the treatment of bipolar psychosis.
Topics: Animals; Antipsychotic Agents; Bipolar Disorder; Humans; Isoindoles; Lurasidone Hydrochloride; Psychotic Disorders; Schizophrenia; Thiazoles | 2015 |
Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain Diseases; Child; Chronic Disease; Clozapine; Comorbidity; Disease Progression; Humans; Magnetic Resonance Imaging; Olanzapine; Piperazines; Prognosis; Psychotic Disorders; Quinolones; Schizophrenia; Thiazoles; Treatment Failure | 2008 |
Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Clozapine; Dibenzothiazepines; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Sulpiride; Thiazoles | 2009 |
Using oral ziprasidone effectively: the food effect and dose-response.
Topics: Administration, Oral; Antipsychotic Agents; Biological Availability; Bipolar Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Energy Intake; Food-Drug Interactions; Humans; Injections, Intramuscular; Intestinal Absorption; Piperazines; Safety; Schizophrenia; Thiazoles; Treatment Outcome | 2009 |
Lurasidone: a new drug in development for schizophrenia.
Topics: Animals; Antipsychotic Agents; Bipolar Disorder; Clinical Trials, Phase II as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Isoindoles; Lurasidone Hydrochloride; Schizophrenia; Thiazoles | 2009 |
Ziprasidone versus other atypical antipsychotics for schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Sulpiride; Thiazoles | 2009 |
Amisulpride versus other atypical antipsychotics for schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Piperazines; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Sulpiride; Thiazoles | 2010 |
Quetiapine versus other atypical antipsychotics for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Medication Adherence; Olanzapine; Piperazines; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles | 2010 |
Olanzapine versus other atypical antipsychotics for schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Sulpiride; Thiazoles | 2010 |
Strategies for successful clinical management of schizophrenia with ziprasidone.
Topics: Antipsychotic Agents; Comorbidity; Humans; Piperazines; Randomized Controlled Trials as Topic; Risk Factors; Schizophrenia; Thiazoles; Treatment Outcome | 2010 |
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Cholesterol; Clinical Trials as Topic; Clozapine; Dibenzothiazepines; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Sulpiride; Thiazoles; Weight Gain | 2010 |
Clozapine versus other atypical antipsychotics for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dibenzothiepins; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles | 2010 |
Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.
Topics: Administration, Oral; Antipsychotic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Drug Interactions; Drug Labeling; Humans; Isoindoles; Lurasidone Hydrochloride; Numbers Needed To Treat; Randomized Controlled Trials as Topic; Schizophrenia; Thiazoles; Treatment Outcome | 2011 |
Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic.
Topics: Akathisia, Drug-Induced; Animals; Antipsychotic Agents; Disorders of Excessive Somnolence; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Humans; Isoindoles; Lurasidone Hydrochloride; Randomized Controlled Trials as Topic; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists; Thiazoles; Treatment Outcome; United States; United States Food and Drug Administration; Weight Gain | 2011 |
Risperidone versus other atypical antipsychotics for schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Sulpiride; Thiazoles | 2011 |
Drug safety evaluation of ziprasidone.
Topics: Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Long QT Syndrome; Piperazines; Schizophrenia; Thiazoles | 2011 |
Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Isoindoles; Isoxazoles; Lurasidone Hydrochloride; Piperidines; Schizophrenia; Thiazoles | 2011 |
Lurasidone: a new treatment option for schizophrenia.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Drug Interactions; Humans; Isoindoles; Lurasidone Hydrochloride; Schizophrenia; Thiazoles | 2011 |
Lurasidone: a clinical overview.
Topics: Antipsychotic Agents; Blood Glucose; Body Weight; Humans; Hypotension, Orthostatic; Isoindoles; Long QT Syndrome; Lurasidone Hydrochloride; Schizophrenia; Thiazoles; Treatment Outcome | 2011 |
Lurasidone for schizophrenia: what's different?
Topics: Antipsychotic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Isoindoles; Lurasidone Hydrochloride; Schizophrenia; Thiazoles | 2012 |
Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Bipolar Disorder; Child; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Dose-Response Relationship, Drug; Electrocardiography; Humans; Long QT Syndrome; Piperazines; Randomized Controlled Trials as Topic; Schizophrenia; Thiazoles | 2012 |
Lurasidone (latuda®): an atypical antipsychotic.
Topics: Antipsychotic Agents; Humans; Isoindoles; Lurasidone Hydrochloride; Schizophrenia; Thiazoles | 2012 |
A review of published evidence reporting on the efficacy and pharmacology of lurasidone.
Topics: Bipolar Disorder; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cognition Disorders; Double-Blind Method; Humans; Isoindoles; Lurasidone Hydrochloride; Randomized Controlled Trials as Topic; Schizophrenia; Thiazoles | 2012 |
Update on the development of lurasidone as a treatment for patients with acute schizophrenia.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Clinical Trials as Topic; Cognition; Humans; Isoindoles; Lurasidone Hydrochloride; Metabolomics; Receptors, N-Methyl-D-Aspartate; Receptors, Serotonin; Schizophrenia; Thiazoles | 2012 |
ACS chemical neuroscience molecule spotlight on latuda (lurasidone; SM-13,496).
Topics: Animals; Antipsychotic Agents; Clinical Trials as Topic; Dopamine Antagonists; Humans; Isoindoles; Lurasidone Hydrochloride; Neurosciences; Schizophrenia; Serotonin Antagonists; Serotonin Receptor Agonists; Societies, Scientific; Thiazoles | 2011 |
Changes in weight, plasma lipids, and glucose in adults treated with ziprasidone: a comprehensive analysis of pfizer-initiated clinical trials.
Topics: Antipsychotic Agents; Bipolar Disorder; Blood Glucose; Body Mass Index; Body Weight; Clinical Trials as Topic; Drug Industry; Fasting; Humans; Lipids; Piperazines; Psychotic Disorders; Randomized Controlled Trials as Topic; Schizophrenia; Thiazoles; Time Factors | 2012 |
Iloperidone, asenapine and lurasidone: a primer on their current status.
Topics: Adult; Animals; Antipsychotic Agents; Bipolar Disorder; Dibenzocycloheptenes; Drug Approval; Heterocyclic Compounds, 4 or More Rings; Humans; Isoindoles; Isoxazoles; Lurasidone Hydrochloride; Piperidines; Schizophrenia; Thiazoles; United States; United States Food and Drug Administration | 2012 |
Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.
Topics: Antipsychotic Agents; Bipolar Disorder; Blood Glucose; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Isoindoles; Isoxazoles; Lipid Metabolism; Lurasidone Hydrochloride; Paliperidone Palmitate; Piperidines; Pyrimidines; Randomized Controlled Trials as Topic; Schizophrenia; Thiazoles; Weight Gain | 2012 |
Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis.
Topics: Adult; Affective Disorders, Psychotic; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Humans; Hypercholesterolemia; Incidence; Pharmacovigilance; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles | 2012 |
Lurasidone in schizophrenia: new information about dosage and place in therapy.
Topics: Antipsychotic Agents; Isoindoles; Lurasidone Hydrochloride; Schizophrenia; Thiazoles; Treatment Outcome | 2012 |
Lurasidone : in the treatment of schizophrenia.
Topics: Animals; Antipsychotic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Isoindoles; Lurasidone Hydrochloride; Schizophrenia; Thiazoles; Time Factors | 2013 |
Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults.
Topics: Antipsychotic Agents; Dibenzocycloheptenes; Drug Approval; Heterocyclic Compounds, 4 or More Rings; Humans; Isoindoles; Isoxazoles; Lurasidone Hydrochloride; Piperidines; Schizophrenia; Thiazoles | 2013 |
Spotlight on ziprasidone in schizophrenia and schizoaffective disorder.
Topics: Antipsychotic Agents; Humans; Piperazines; Psychotic Disorders; Randomized Controlled Trials as Topic; Schizophrenia; Thiazoles; Treatment Outcome | 2002 |
Continuum of care: stabilizing the acutely agitated patient.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Continuity of Patient Care; Cost-Benefit Analysis; Drug Therapy, Combination; Economics, Pharmaceutical; Humans; Olanzapine; Piperazines; Pirenzepine; Psychomotor Agitation; Schizophrenia; Thiazoles; Treatment Outcome | 2002 |
Ziprasidone in the management of schizophrenia : the QT interval issue in context.
Topics: Antipsychotic Agents; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Piperazines; Risk Assessment; Risk Factors; Schizophrenia; Sex Factors; Thiazoles; Torsades de Pointes | 2003 |
Chlorpromazine equivalent doses for the newer atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chlorpromazine; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; Humans; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Therapeutic Equivalency; Thiazoles | 2003 |
[An introduction to antipsychotics].
Topics: Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Dopamine Antagonists; Humans; Indoles; Isoindoles; Olanzapine; Pirenzepine; Quetiapine Fumarate; Receptors, Dopamine; Receptors, Serotonin; Risperidone; Schizophrenia; Serotonin Antagonists; Thiazoles | 2003 |
Neuropharmacological profile of an atypical antipsychotic, NRA0562.
Topics: Animals; Antipsychotic Agents; Brain; Dopamine Antagonists; Humans; Methamphetamine; Motor Activity; Neuropharmacology; Piperidines; Receptors, Dopamine; Schizophrenia; Serotonin Antagonists; Thiazoles | 2003 |
The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.
Topics: Animals; Antipsychotic Agents; Brain; Clinical Trials as Topic; Dopamine; Humans; Membrane Glycoproteins; Membrane Transport Proteins; Neuropeptides; Piperazines; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology; Serotonin; Serotonin Antagonists; Thiazoles; Vesicular Biogenic Amine Transport Proteins | 2003 |
Intramuscular ziprasidone: moving beyond the conventional in the treatment of acute agitation in schizophrenia.
Topics: Acute Disease; Antipsychotic Agents; Brief Psychiatric Rating Scale; Dose-Response Relationship, Drug; Humans; Injections, Intramuscular; Piperazines; Psychomotor Agitation; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Serotonin Antagonists; Thiazoles; Treatment Outcome | 2003 |
Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials.
Topics: Administration, Oral; Antipsychotic Agents; Double-Blind Method; Humans; Piperazines; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Serotonin Antagonists; Thiazoles; Treatment Outcome | 2003 |
Maintaining symptom control: review of ziprasidone long-term efficacy data.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Humans; Long-Term Care; Piperazines; Schizophrenia; Schizophrenic Psychology; Serotonin Antagonists; Thiazoles; Treatment Outcome | 2003 |
Tolerability of ziprasidone: an expanding perspective.
Topics: Administration, Oral; Antipsychotic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Injections, Intramuscular; Long-Term Care; Piperazines; Schizophrenia; Schizophrenic Psychology; Serotonin Antagonists; Thiazoles | 2003 |
Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions.
Topics: Antipsychotic Agents; Benzodiazepines; Chemistry, Pharmaceutical; Clinical Trials as Topic; Clozapine; Cytochrome P-450 Enzyme System; Dibenzothiazepines; Drug Interactions; Drug Monitoring; Humans; Molecular Structure; Olanzapine; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles | 2004 |
Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Patient Compliance; Piperazines; Polypharmacy; Quetiapine Fumarate; Quinolones; Research Design; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2004 |
New antipsychotics and schizophrenia: a review on efficacy and side effects.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Cognition; Dibenzothiazepines; Drug Interactions; Humans; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2004 |
[Current pharmacotherapy of schizophrenia].
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Serotonin Antagonists; Sulpiride; Thiazoles | 2004 |
[Ziprasidone. A new second-generation antipsychotic agent].
Topics: Administration, Oral; Antipsychotic Agents; Dopamine Antagonists; Humans; Injections, Intramuscular; Piperazines; Psychotic Disorders; Schizophrenia; Serotonin Antagonists; Thiazoles | 2004 |
Atypical antipsychotics in the treatment of children and adolescents: clinical applications.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Benzodiazepines; Bipolar Disorder; Child; Child Development Disorders, Pervasive; Clozapine; Dibenzothiazepines; Humans; Mental Disorders; Olanzapine; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Tic Disorders | 2004 |
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update.
Topics: Algorithms; Ambulatory Care; Ambulatory Care Facilities; Antipsychotic Agents; Aripiprazole; Clozapine; Decision Trees; Drug Administration Schedule; Drug Therapy, Combination; Humans; Piperazines; Practice Guidelines as Topic; Quinolones; Schizophrenia; Schizophrenic Psychology; Texas; Thiazoles; Treatment Outcome | 2004 |
[Paralytic ileus during haloperidol therapy].
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Fatal Outcome; Haloperidol; Humans; Intestinal Pseudo-Obstruction; Male; Piperazines; Schizophrenia; Schizophrenic Psychology; Thiazoles | 2004 |
Atypical antipsychotics and diabetes mellitus.
Topics: Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus; Dibenzothiazepines; Glucose; Humans; Insulin Resistance; Islets of Langerhans; Obesity; Olanzapine; Pancreas; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles | 2004 |
An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Double-Blind Method; Drug Industry; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Research Support as Topic; Retrospective Studies; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2004 |
Ziprasidone: efficacy, tolerability, and emerging data on wide-ranging effectiveness.
Topics: Antipsychotic Agents; Chemistry, Pharmaceutical; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Tolerance; Humans; Piperazines; Schizophrenia; Thiazoles | 2005 |
Ziprasidone: a novel psychotropic with unique properties.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Humans; Mental Disorders; Piperazines; Schizophrenia; Thiazoles | 2004 |
Efficacy of olanzapine and ziprasidone for the treatment of schizophrenia: a systematic review.
Topics: Antipsychotic Agents; Benzodiazepines; Drug Evaluation; Humans; Meta-Analysis as Topic; Olanzapine; Piperazines; Schizophrenia; Thiazoles | 2005 |
Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Dyskinesia, Drug-Induced; Humans; Incidence; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2005 |
Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Humans; Male; Middle Aged; Olanzapine; Patient Dropouts; Piperazines; Psychiatric Status Rating Scales; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Failure; Treatment Refusal | 2005 |
Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Double-Blind Method; Female; Humans; Male; Olanzapine; Patient Dropouts; Piperazines; Psychiatric Status Rating Scales; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Research Design; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Failure; Treatment Outcome | 2006 |
Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder.
Topics: Antipsychotic Agents; Area Under Curve; Humans; Injections, Intramuscular; Long QT Syndrome; Piperazines; Psychotic Disorders; Schizophrenia; Tablets; Thiazoles; Treatment Outcome | 2006 |
Treatment of psychosis: 30 years of progress.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Receptors, Dopamine; Receptors, Serotonin; Risperidone; Schizophrenia; Thiazoles | 2006 |
Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials.
Topics: Affective Symptoms; Antipsychotic Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Longitudinal Studies; Piperazines; Randomized Controlled Trials as Topic; Schizophrenia; Thiazoles; Treatment Outcome | 2007 |
Metabolic effects of the atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus; Dibenzothiazepines; Dyslipidemias; Glucose Metabolism Disorders; Humans; Insulin Resistance; Mental Disorders; Obesity; Olanzapine; Phenothiazines; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2007 |
Managing the acutely agitated and psychotic patient.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Emergencies; Humans; Olanzapine; Piperazines; Psychomotor Agitation; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2007 |
Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Double-Blind Method; Humans; Injections, Intramuscular; Olanzapine; Piperazines; Psychomotor Agitation; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Thiazoles; Treatment Outcome | 2007 |
A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Double-Blind Method; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Research Design; Risperidone; Schizophrenia; Sleep Stages; Thiazoles; Treatment Outcome | 2008 |
Problems with CATIE. Phase 1: Looking back--what the clinician needs to know.
Topics: Antidepressive Agents, Second-Generation; Basal Ganglia Diseases; Benzodiazepines; Clinical Trials, Phase I as Topic; Cost-Benefit Analysis; Dibenzothiazepines; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risk; Risperidone; Schizophrenia; Thiazoles | 2008 |
Dopamine agonists in schizophrenia: a review.
Topics: Antipsychotic Agents; Autoreceptors; Azepines; Benzothiazoles; Dopamine Agonists; Humans; Pramipexole; Schizophrenia; Thiazoles | 1995 |
The new generation of antipsychotic drugs.
Topics: Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Schizophrenia; Thiazoles | 1996 |
Tardive dyskinesia in affective disorders.
Topics: Adult; Affective Disorders, Psychotic; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Carbamazepine; Controlled Clinical Trials as Topic; Dibenzothiazepines; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Imidazoles; Indoles; Male; Olanzapine; Piperazines; Pirenzepine; Psychotic Disorders; Quetiapine Fumarate; Risk Assessment; Risk Factors; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 1999 |
The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Clozapine; Depression; Depressive Disorder; Dibenzothiazepines; Hostility; Humans; Multicenter Studies as Topic; Olanzapine; Piperazines; Pirenzepine; Psychiatric Status Rating Scales; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Suicide; Thiazoles; Treatment Outcome | 2000 |
Ziprasidone for schizophrenia and severe mental illness.
Topics: Antipsychotic Agents; Humans; Piperazines; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Thiazoles | 2000 |
[New i.e. atypical neuroleptic agents for negative symptoms of schizophrenia: results and methodological problems of evaluation].
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dibenzothiepins; Double-Blind Method; Dyskinesia, Drug-Induced; Humans; Imidazoles; Indoles; Neurotransmitter Agents; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Schizophrenic Psychology; Sulpiride; Thiazoles | 2000 |
Ziprasidone for schizophrenia and severe mental illness.
Topics: Antipsychotic Agents; Humans; Piperazines; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Thiazoles | 2000 |
Ziprasidone: comprehensive overview and clinical use of a novel antipsychotic.
Topics: Animals; Antipsychotic Agents; Clinical Trials as Topic; Humans; Piperazines; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Serotonin Antagonists; Thiazoles | 2000 |
[Pharmacological characteristics of perospirone hydrochloride, a novel antipsychotic agent].
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Humans; Indoles; Isoindoles; Schizophrenia; Serotonin Antagonists; Thiazoles | 2000 |
Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dibenzothiepins; Dopamine Antagonists; Drug Monitoring; Haloperidol; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Receptors, Dopamine D2; Receptors, Dopamine D4; Risperidone; Schizophrenia; Schizophrenic Psychology; Serotonin Antagonists; Sulpiride; Thiazoles; Treatment Outcome | 2001 |
[Atypical neuroleptics: new approaches to drug therapy of schizophrenic disorders].
Topics: Aged; Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Controlled Clinical Trials as Topic; Dibenzothiazepines; Dibenzothiepins; Haloperidol; Humans; Imidazoles; Indoles; Multicenter Studies as Topic; Olanzapine; Piperazines; Pirenzepine; Placebos; Quetiapine Fumarate; Risperidone; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Sulpiride; Thiazoles | 2000 |
The pharmacology of weight gain with antipsychotics.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Eating; Humans; Olanzapine; Piperazines; Pirenzepine; Psychotic Disorders; Quetiapine Fumarate; Rats; Receptors, Neurotransmitter; Schizophrenia; Thiazoles; Weight Gain | 2001 |
Ziprasidone, a new atypical antipsychotic drug.
Topics: Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Topic; Drug Interactions; Humans; Piperazines; Psychotic Disorders; Schizophrenia; Thiazoles; Tourette Syndrome | 2001 |
Perospirone.
Topics: Animals; Antipsychotic Agents; Clinical Trials as Topic; Humans; Indoles; Isoindoles; Psychiatric Status Rating Scales; Schizophrenia; Thiazoles; Treatment Outcome | 2001 |
Ziprasidone: a new atypical antipsychotic.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Dibenzothiazepines; Dopamine Antagonists; Drug Interactions; Guidelines as Topic; Humans; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Risperidone; Schizophrenia; Serotonin Antagonists; Thiazoles; Time Factors; Tourette Syndrome | 2001 |
Review of atypical antipsychotics and weight gain.
Topics: Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clinical Trials as Topic; Clozapine; Dibenzothiazepines; Dose-Response Relationship, Drug; Hospitalization; Humans; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Research Design; Schizophrenia; Thiazoles; Weight Gain | 2001 |
Focus on ziprasidone.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Dopamine Antagonists; Humans; Piperazines; Psychotic Disorders; Schizophrenia; Serotonin Antagonists; Thiazoles; Treatment Outcome | 2001 |
Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia.
Topics: Administration, Oral; Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Topic; Drug Interactions; Drug Overdose; Humans; Injections, Intramuscular; Piperazines; Psychotic Disorders; Schizophrenia; Thiazoles; Tourette Syndrome | 2002 |
Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dosage Forms; Humans; Isoxazoles; Olanzapine; Piperazines; Piperidines; Pirenzepine; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2002 |
Ziprasidone: the fifth atypical antipsychotic.
Topics: Acute Disease; Antipsychotic Agents; Basal Ganglia Diseases; Body Weight; Headache; Humans; Injections, Intramuscular; Long QT Syndrome; Nausea; Piperazines; Randomized Controlled Trials as Topic; Schizophrenia; Thiazoles; Treatment Outcome; Weight Gain | 2002 |
Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder.
Topics: Administration, Oral; Antipsychotic Agents; Clinical Trials as Topic; Drug Interactions; Humans; Injections, Intramuscular; Piperazines; Psychotic Disorders; Schizophrenia; Thiazoles; Treatment Outcome | 2002 |
Perospirone (Sumitomo Pharmaceuticals).
Topics: Animals; Clinical Trials as Topic; Dopamine Antagonists; Humans; Indoles; Isoindoles; Schizophrenia; Serotonin Antagonists; Technology, Pharmaceutical; Thiazoles | 2002 |
173 trial(s) available for thiazoles and Schizophrenia
| Article | Year |
|---|---|
Low-Dose Ziprasidone in Combination with Sertraline for First-Episode Drug-Naïve Patients with Schizophrenia: a Randomized Controlled Trial.
Topics: Antipsychotic Agents; Double-Blind Method; Humans; Piperazines; Psychiatric Status Rating Scales; Schizophrenia; Sertraline; Thiazoles; Treatment Outcome | 2022 |
Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Follow-Up Studies; Haloperidol; Humans; Male; Olanzapine; Outcome Assessment, Health Care; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Young Adult | 2020 |
Course of Psychosis in Schizophrenia With Alcohol Use Disorder: A Post Hoc Analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness in Schizophrenia Phase 1 Study.
Topics: Adult; Alcoholism; Antipsychotic Agents; Comorbidity; Female; Hospitalization; Humans; Male; Olanzapine; Outcome Assessment, Health Care; Perphenazine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Severity of Illness Index; Symptom Flare Up; Thiazoles; Time Factors | 2020 |
Metabolic Effects of 7 Antipsychotics on Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Male; Metabolic Syndrome; Olanzapine; Piperazines; Quetiapine Fumarate; Risk Factors; Risperidone; Schizophrenia; Thiazoles; Triglycerides | 2020 |
A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: A pragmatic clinical trial in first episode psychosis patients.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Energy Metabolism; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Piperazines; Prospective Studies; Psychotic Disorders; Quetiapine Fumarate; Schizophrenia; Thiazoles; Time Factors; Weight Gain; Young Adult | 2020 |
Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Haloperidol; Humans; Incidence; Male; Olanzapine; Piperazines; Prospective Studies; Psychotic Disorders; Quetiapine Fumarate; Risk Factors; Risperidone; Schizophrenia; Thiazoles; Young Adult | 2017 |
Dose reduction of high-dose first-generation antipsychotics or switch to ziprasidone in long-stay patients with schizophrenia: A 1-year double-blind randomized clinical trial.
Topics: Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Female; Humans; Male; Middle Aged; Piperazines; Schizophrenia; Thiazoles; Treatment Outcome | 2018 |
Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Follow-Up Studies; Humans; Male; Outcome Assessment, Health Care; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Schizophrenia; Thiazoles; Young Adult | 2018 |
Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled Study.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Haloperidol; Humans; Interpersonal Relations; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Risk Assessment; Schizophrenia; Severity of Illness Index; Thiazoles; Time Factors; Treatment Outcome | 2019 |
The role of weight gain in explaining the effects of antipsychotic drugs on positive and negative symptoms: An analysis of the CATIE schizophrenia trial.
Topics: Adult; Antipsychotic Agents; Body-Weight Trajectory; Female; Humans; Male; Middle Aged; Olanzapine; Perphenazine; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome; Weight Gain | 2019 |
Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Analysis of Variance; Antipsychotic Agents; Basal Ganglia Diseases; Body Mass Index; Body Weight; Dibenzothiazepines; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Humans; Isoindoles; Lurasidone Hydrochloride; Male; Middle Aged; Models, Statistical; Prospective Studies; Psychiatric Status Rating Scales; Quetiapine Fumarate; Schizophrenia; Severity of Illness Index; Thiazoles; Time Factors; Waist Circumference; Young Adult | 2013 |
Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study.
Topics: Adult; Antipsychotic Agents; Brain; Case-Control Studies; Dopamine Antagonists; Female; Half-Life; Humans; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Prolactin; Raclopride; Receptors, Dopamine D2; Receptors, Dopamine D3; Schizophrenia; Thiazoles; Time Factors; Young Adult | 2013 |
Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; International Cooperation; Isoindoles; Lurasidone Hydrochloride; Male; Middle Aged; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Thiazoles; Treatment Outcome; Young Adult | 2013 |
Aripiprazole, ziprasidone, and quetiapine in the treatment of first-episode nonaffective psychosis: results of a 6-week, randomized, flexible-dose, open-label comparison.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Dose-Response Relationship, Drug; Female; Humans; Male; Piperazines; Prospective Studies; Quetiapine Fumarate; Quinolones; Schizophrenia; Thiazoles; Treatment Outcome; Young Adult | 2013 |
Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; China; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Injections, Intramuscular; Least-Squares Analysis; Male; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Schizophrenia; Thiazoles; Time Factors; Young Adult | 2013 |
Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Drug Administration Schedule; Female; Humans; Isoindoles; Lurasidone Hydrochloride; Male; Olanzapine; Psychotic Disorders; Quetiapine Fumarate; Schizophrenia; Thiazoles; Time Factors; Treatment Failure; Treatment Outcome | 2013 |
Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Female; Humans; Isoindoles; Lurasidone Hydrochloride; Male; Olanzapine; Placebos; Psychiatric Status Rating Scales; Schizophrenia; Thiazoles; Time Factors; Treatment Outcome | 2013 |
Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study.
Topics: Adult; Antipsychotic Agents; Dibenzothiazepines; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Humans; Isoindoles; Kaplan-Meier Estimate; Lurasidone Hydrochloride; Male; Middle Aged; Psychiatric Status Rating Scales; Quetiapine Fumarate; Schizophrenia; Secondary Prevention; Thiazoles; Treatment Outcome | 2013 |
[Effects of ziprasidone and olanzapine on glucose and lipid metabolism in first-episode schizophrenia].
Topics: Adolescent; Adult; Benzodiazepines; Blood Glucose; Female; Humans; Lipid Metabolism; Male; Middle Aged; Olanzapine; Piperazines; Schizophrenia; Thiazoles; Young Adult | 2013 |
Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Olanzapine; Piperazines; Predictive Value of Tests; Prolactin; Receptors, Dopamine D2; Risperidone; Schizophrenia; Sensitivity and Specificity; Thiazoles | 2013 |
Annual cost of relapses and relapse-related hospitalizations in adults with schizophrenia: results from a 12-month, double-blind, comparative study of lurasidone vs quetiapine extended-release.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cost-Benefit Analysis; Delayed-Action Preparations; Dibenzothiazepines; Double-Blind Method; Female; Health Services; Hospitalization; Humans; Isoindoles; Lurasidone Hydrochloride; Male; Mental Health Services; Middle Aged; Models, Economic; Quetiapine Fumarate; Schizophrenia; Thiazoles; Young Adult | 2013 |
High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study.
Topics: Adult; Antipsychotic Agents; Blood Pressure; Female; Humans; Long QT Syndrome; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Thiazoles; Time Factors; Treatment Outcome; United States | 2013 |
Effects of ziprasidone and olanzapine on body composition and metabolic parameters: an open-label comparative pilot study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Appetite; Benzodiazepines; Body Composition; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Energy Metabolism; Female; Humans; Male; Middle Aged; Olanzapine; Pilot Projects; Piperazines; Psychotic Disorders; Schizophrenia; Thiazoles; Weight Gain; Young Adult | 2013 |
A twenty-four-week, open-label study on ziprasidone's efficacy and influence on glucolipid metabolism in patients with schizophrenia and metabolic disorder.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol, HDL; Clozapine; Cognition Disorders; Female; Follow-Up Studies; Humans; Male; Metabolic Syndrome; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Schizophrenia; Thiazoles; Triglycerides | 2013 |
Estimated dopamine D₂ receptor occupancy and remission in schizophrenia: analysis of the CATIE data.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Female; Humans; Male; Middle Aged; Nonlinear Dynamics; Olanzapine; Piperazines; Protein Binding; Psychiatric Status Rating Scales; Receptors, Dopamine D2; Remission Induction; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Time Factors; Treatment Outcome; United States | 2013 |
Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studies.
Topics: Adult; Cross-Over Studies; Female; Food-Drug Interactions; Humans; Isoindoles; Lurasidone Hydrochloride; Male; Middle Aged; Schizophrenia; Thiazoles | 2013 |
Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension.
Topics: Adult; Antipsychotic Agents; Cognition; Delayed-Action Preparations; Dibenzothiazepines; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Isoindoles; Lurasidone Hydrochloride; Male; Psychiatric Status Rating Scales; Quetiapine Fumarate; Schizophrenia; Schizophrenic Psychology; Thiazoles; Time Factors | 2013 |
D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Algorithms; Antipsychotic Agents; Benzamides; Brain; Dose-Response Relationship, Drug; Female; Humans; Isoindoles; Lurasidone Hydrochloride; Male; Middle Aged; Positron-Emission Tomography; Psychiatric Status Rating Scales; Psychotic Disorders; Pyrrolidines; Receptors, Dopamine D2; Schizophrenia; Statistics as Topic; Thiazoles; Young Adult | 2014 |
Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Hallucinations; Hospitalization; Humans; Male; Middle Aged; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2013 |
Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study.
Topics: Adolescent; Antipsychotic Agents; Double-Blind Method; Early Termination of Clinical Trials; Female; Humans; Male; Piperazines; Placebos; Schizophrenia; Thiazoles; Treatment Outcome | 2013 |
Augmentation of clozapine with ziprasidone in refractory schizophrenia: a double-blind, placebo-controlled study.
Topics: Adult; Antipsychotic Agents; Clozapine; Cognition; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Electrocardiography; Female; Heart Rate; Humans; Italy; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Thiazoles; Time Factors; Treatment Outcome; Young Adult | 2014 |
Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.
Topics: Adult; Aggression; Amisulpride; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Hostility; Humans; Male; Middle Aged; Olanzapine; Perphenazine; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Sulpiride; Thiazoles | 2014 |
Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cognition Disorders; Dibenzothiazepines; Disorders of Excessive Somnolence; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Isoindoles; Lurasidone Hydrochloride; Male; Middle Aged; Psychiatric Status Rating Scales; Quetiapine Fumarate; Schizophrenia; Thiazoles; Treatment Outcome; Young Adult | 2014 |
Noninferiority of perphenazine vs. three second-generation antipsychotics in chronic schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Olanzapine; Perphenazine; Piperazines; Quetiapine Fumarate; Risperidone; Sample Size; Schizophrenia; Thiazoles; Treatment Outcome | 2014 |
Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone.
Topics: Adult; Alleles; Antipsychotic Agents; Aripiprazole; Body Mass Index; Female; Follow-Up Studies; Genotype; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Piperazines; Polymorphism, Genetic; Quinolones; Receptors, Adrenergic, alpha-2; Schizophrenia; Thiazoles; Weight Gain; Weight Loss | 2014 |
Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Body Mass Index; China; Delayed-Action Preparations; Diagnostic and Statistical Manual of Mental Disorders; Female; Follow-Up Studies; Humans; Hyperglycemia; Hyperlipidemias; Isoxazoles; Male; Metabolic Diseases; Paliperidone Palmitate; Piperazines; Psychiatric Status Rating Scales; Pyrimidines; Quinolones; Schizophrenia; Thiazoles; Weight Gain; Young Adult | 2012 |
Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Drug Substitution; Female; Humans; Isoindoles; Lurasidone Hydrochloride; Male; Middle Aged; Olanzapine; Outpatients; Piperazines; Quality of Life; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2014 |
The effect of ziprasidone on metabolic syndrome risk factors in subjects with schizophrenia: a 1 year, open-label, prospective study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Humans; Male; Metabolic Syndrome; Middle Aged; Piperazines; Prospective Studies; Risk Factors; Schizophrenia; Thiazoles; Young Adult | 2014 |
Completed and attempted suicides among 18,154 subjects with schizophrenia included in a large simple trial.
Topics: Adult; Antipsychotic Agents; Asia; Benzodiazepines; Europe; Female; Follow-Up Studies; Humans; Latin America; Male; Middle Aged; Olanzapine; Piperazines; Risk Factors; Schizophrenia; Suicide; Suicide, Attempted; Thiazoles; Time Factors; United States | 2014 |
Open prospective study of ziprasidone in patients with schizophrenia with depressive symptoms: a multicenter study.
Topics: Adult; Antipsychotic Agents; Comorbidity; Depression; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Schizophrenia; Thiazoles; Treatment Outcome | 2015 |
Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Depressive Disorder; Double-Blind Method; Female; Humans; Isoindoles; Lurasidone Hydrochloride; Male; Middle Aged; Psychiatric Status Rating Scales; Schizophrenia; Thiazoles; Young Adult | 2015 |
Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Biomarkers, Pharmacological; Dibenzothiazepines; Female; Genotyping Techniques; Glucagon-Like Peptide-1 Receptor; Haplotypes; Humans; Male; Models, Genetic; Olanzapine; Perphenazine; Piperazines; Polymorphism, Single Nucleotide; Quetiapine Fumarate; Receptors, Glucagon; Regression Analysis; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome; Weight Gain; White People | 2014 |
Schizophrenia gene expression profile reverted to normal levels by antipsychotics.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Humans; Longitudinal Studies; Male; Olanzapine; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Transcriptome; Treatment Outcome | 2014 |
Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data.
Topics: Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Depressive Disorder, Major; Double-Blind Method; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome | 2015 |
HTR1A Gene Polymorphisms and 5-HT1A Receptor Partial Agonist Antipsychotics Efficacy in Schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Haplotypes; Humans; Isoindoles; Male; Middle Aged; Polymorphism, Single Nucleotide; Receptor, Serotonin, 5-HT1A; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Thiazoles; Treatment Outcome | 2015 |
Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial.
Topics: Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dopamine Agonists; Dopamine D2 Receptor Antagonists; Drug Partial Agonism; Female; Humans; Isoindoles; Male; Middle Aged; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome; Young Adult | 2015 |
Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia.
Topics: Adolescent; Adult; Aged; Alcoholism; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Comorbidity; Cross-Sectional Studies; Dibenzothiazepines; Double-Blind Method; Female; Humans; Illicit Drugs; Male; Middle Aged; Olanzapine; Perphenazine; Piperazines; Psychiatric Status Rating Scales; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Smoking; Smoking Prevention; Substance-Related Disorders; Thiazoles; Young Adult | 2015 |
Relating Spontaneously Reported Extrapyramidal Adverse Events to Movement Disorder Rating Scales.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Double-Blind Method; Haloperidol; Humans; Middle Aged; Piperazines; Schizophrenia; Severity of Illness Index; Thiazoles; Young Adult | 2015 |
Serotonin 7 Receptor Variants Are Not Associated with Response to Second-Generation Antipsychotics in Japanese Schizophrenia Patients.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Asian People; Female; Humans; Isoindoles; Japan; Linkage Disequilibrium; Male; Middle Aged; Polymorphism, Single Nucleotide; Precision Medicine; Psychiatric Status Rating Scales; Receptors, Serotonin; Schizophrenia; Thiazoles; Treatment Outcome | 2015 |
Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Incidence; Male; Metabolic Diseases; Middle Aged; Non-alcoholic Fatty Liver Disease; Piperazines; Prospective Studies; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Young Adult | 2016 |
An assessor-blinded, randomized comparison of efficacy and tolerability of switching from olanzapine to ziprasidone and the combination of both in schizophrenia spectrum disorders.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Drug Substitution; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Male; Metabolic Syndrome; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Severity of Illness Index; Single-Blind Method; Thiazoles; Treatment Outcome; Weight Gain | 2017 |
Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basic Helix-Loop-Helix Transcription Factors; Double-Blind Method; Female; Genome-Wide Association Study; Glial Cell Line-Derived Neurotrophic Factor Receptors; Humans; Isoxazoles; Male; Middle Aged; Nerve Tissue Proteins; Pharmacogenetics; Piperazines; Piperidines; Polymorphism, Single Nucleotide; Pseudogenes; Receptors, AMPA; Schizophrenia; Tenascin; Thiazoles; Transcription Factors; Young Adult | 2009 |
Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Carrier Proteins; CELF Proteins; Cytoskeletal Proteins; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Gene Frequency; Genome-Wide Association Study; Genotype; Humans; Intracellular Signaling Peptides and Proteins; Isoxazoles; Linear Models; Linkage Disequilibrium; Long QT Syndrome; Male; Middle Aged; Neuregulins; Organic Anion Transporters; Pharmacogenetics; Phosphoproteins; Phosphotransferases (Alcohol Group Acceptor); Piperazines; Piperidines; Polymorphism, Single Nucleotide; RNA-Binding Proteins; Schizophrenia; Thiazoles; Young Adult | 2009 |
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cardiovascular Diseases; Dibenzothiazepines; Female; Humans; Male; Middle Aged; Olanzapine; Perphenazine; Piperazines; Quetiapine Fumarate; Risk Factors; Risperidone; Schizophrenia; Thiazoles; Triglycerides | 2008 |
Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Female; Humans; Long QT Syndrome; Male; Middle Aged; Piperazines; Prolactin; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Thiazoles; Treatment Outcome; Young Adult | 2009 |
Changes in sexual function for outpatients with schizophrenia or other psychotic disorders treated with ziprasidone in clinical practice settings: a 3-month prospective, observational study.
Topics: Adolescent; Adult; Antipsychotic Agents; Female; Humans; Male; Piperazines; Prospective Studies; Psychotic Disorders; Schizophrenia; Sexual Dysfunction, Physiological; Thiazoles | 2008 |
Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cholesterol; Chronic Disease; Dibenzothiazepines; Drug Tolerance; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Triglycerides; Young Adult | 2009 |
Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder.
Topics: Adolescent; Antipsychotic Agents; Bipolar Disorder; Child; Dose-Response Relationship, Drug; Electrocardiography; Female; Humans; Male; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Severity of Illness Index; Thiazoles | 2008 |
Long-term improvement in efficacy and safety after switching to ziprasidone in stable outpatients with schizophrenia.
Topics: Adolescent; Adult; Ambulatory Care; Antipsychotic Agents; Female; Follow-Up Studies; Humans; Long-Term Care; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Thiazoles; Treatment Outcome; Young Adult | 2008 |
Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone).
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Benzamides; Binding, Competitive; Carbon Radioisotopes; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Fluorine Radioisotopes; Humans; Male; Piperazines; Positron-Emission Tomography; Pyrrolidines; Raclopride; Radiopharmaceuticals; Receptors, Dopamine D2; Receptors, Dopamine D3; Schizophrenia; Thiazoles; Time Factors; Young Adult | 2008 |
The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial.
Topics: Adult; Antipsychotic Agents; Biological Availability; Bipolar Disorder; Cross-Over Studies; Dietary Fats; Drug Administration Schedule; Energy Intake; Female; Food-Drug Interactions; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Schizophrenia; Thiazoles; Young Adult | 2009 |
A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study.
Topics: Adult; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Humans; Male; Piperazines; Risperidone; Schizophrenia; Severity of Illness Index; Thiazoles | 2009 |
Reduction of functional disability with atypical antipsychotic treatment: a randomized long term comparison of ziprasidone and haloperidol.
Topics: Adult; Antipsychotic Agents; Chi-Square Distribution; Cognition Disorders; Double-Blind Method; Female; Haloperidol; Humans; Longitudinal Studies; Male; Middle Aged; Neuropsychological Tests; Piperazines; Psychiatric Status Rating Scales; Schizophrenia; Thiazoles; Time Factors; Treatment Outcome | 2009 |
In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Dose-Response Relationship, Drug; Female; Humans; Hyperglycemia; Lipid Metabolism; Lipoproteins, HDL; Male; Middle Aged; Olanzapine; Piperazines; Prediabetic State; Predictive Value of Tests; Randomized Controlled Trials as Topic; Schizophrenia; Thiazoles; Time Factors; Treatment Outcome | 2009 |
Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Body Weight; Clozapine; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucose; Humans; Italy; Lipids; Male; Middle Aged; Patient Compliance; Piperazines; Psychiatric Status Rating Scales; Quality of Life; Schizophrenia; Schizophrenic Psychology; Thiazoles; Young Adult | 2009 |
Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Chronic Disease; Clozapine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hyperglycemia; Insulin Resistance; Male; Middle Aged; Morbidity; Olanzapine; Piperazines; Schizophrenia; Thiazoles; Time Factors | 2009 |
Effectiveness and tolerability of oral ziprasidone in psychiatric inpatients with an acute exacerbation of schizophrenia or schizoaffective disorder: a multicenter, prospective, and naturalistic study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Drug Administration Schedule; Female; Hospitalization; Humans; In Vitro Techniques; Length of Stay; Piperazines; Prospective Studies; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Thiazoles; Treatment Outcome | 2009 |
Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials.
Topics: Acute Disease; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperazines; Proportional Hazards Models; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Thiazoles; Time Factors; Treatment Outcome | 2009 |
Effect of perospirone on P300 electrophysiological activity and social cognition in schizophrenia: a three-dimensional analysis with sloreta.
Topics: Adult; Antipsychotic Agents; Brain Mapping; Cognition; Event-Related Potentials, P300; Female; Frontal Lobe; Functional Laterality; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Isoindoles; Magnetoencephalography; Male; Memory; Middle Aged; Neuropsychological Tests; Outpatients; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Social Perception; Thiazoles; Verbal Learning; Young Adult | 2009 |
Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Patient Dropouts; Piperazines; Psychiatric Status Rating Scales; Quality of Life; Remission Induction; Schizophrenia; Schizophrenic Psychology; Thiazoles; Time Factors; Treatment Outcome; Young Adult | 2009 |
Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.
Topics: Acute Disease; Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Double-Blind Method; Female; Humans; Isoindoles; Lurasidone Hydrochloride; Male; Middle Aged; Psychometrics; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome; Young Adult | 2009 |
Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Thiazoles | 2009 |
Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial.
Topics: Adult; Alanine Transaminase; Antipsychotic Agents; Aspartate Aminotransferases; Basal Ganglia Diseases; Benzodiazepines; Biperiden; Blood Glucose; Body Weight; Cholesterol; Chronic Disease; Electrocardiography; Female; Humans; Male; Muscarinic Antagonists; Olanzapine; Piperazines; Prolactin; Psychiatric Status Rating Scales; Psychometrics; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Thiazoles; Triglycerides; Young Adult | 2011 |
Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Female; Humans; Isoindoles; Male; Middle Aged; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles | 2009 |
Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Double-Blind Method; Female; Genetic Markers; Genotype; Humans; Isoxazoles; Likelihood Functions; Male; Middle Aged; Odds Ratio; Pharmacogenetics; Piperazines; Piperidines; Polymorphism, Single Nucleotide; Probability; Psychiatric Status Rating Scales; Psychometrics; Schizophrenia; Thiazoles; Treatment Outcome | 2009 |
Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Body Weight; Clozapine; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucose; Humans; Italy; Lipids; Male; Middle Aged; Patient Compliance; Piperazines; Psychiatric Status Rating Scales; Quality of Life; Schizophrenia; Schizophrenic Psychology; Thiazoles; Young Adult | 2009 |
Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Chromosomes, Human, Pair 4; Dibenzothiazepines; Double-Blind Method; Follow-Up Studies; Genome-Wide Association Study; Humans; Olanzapine; Perphenazine; Pharmacogenetics; Piperazines; Polymorphism, Single Nucleotide; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2011 |
Ziprasidone in Black patients with schizophrenia: analysis of four short-term, double-blind studies.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Black People; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Thiazoles; Treatment Outcome; Young Adult | 2009 |
Psychosocial functioning and health-related quality of life in children and adolescents treated with open-label ziprasidone for bipolar mania, schizophrenia, or schizoaffective disorder.
Topics: Adolescent; Antipsychotic Agents; Bipolar Disorder; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Health Status; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quality of Life; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Social Behavior; Thiazoles; Treatment Outcome | 2009 |
Absence of weight gain association with the HTR2C -759C/T polymorphism in patients with schizophrenia treated with iloperidone.
Topics: Analysis of Variance; Antipsychotic Agents; Female; Follow-Up Studies; Gene Frequency; Genotype; Humans; Isoxazoles; Male; Piperazines; Piperidines; Polymorphism, Genetic; Receptor, Serotonin, 5-HT2C; Schizophrenia; Thiazoles; Weight Gain | 2010 |
Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Electrocardiography; Female; Haloperidol; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Schizophrenia; Thiazoles | 2010 |
Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST).
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Haloperidol; Humans; Male; Medication Adherence; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Quetiapine Fumarate; ROC Curve; Schizophrenia; Schizophrenic Psychology; Sulpiride; Surveys and Questionnaires; Thiazoles; Treatment Outcome | 2010 |
Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Aged; Antipsychotic Agents; Blood Pressure; Dose-Response Relationship, Drug; Electrocardiography; Female; Haloperidol; Heart Rate; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Schizophrenia; Single-Blind Method; Thiazoles; Young Adult | 2010 |
Switching from conventional antipsychotics to ziprasidone: a randomized, open-label comparison of regimen strategies.
Topics: Adult; Aged; Antipsychotic Agents; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperazines; Schizophrenia; Thiazoles; Treatment Outcome | 2010 |
Short term neurocognitive effects of treatment with ziprasidone and olanzapine in recent onset schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Neuropsychological Tests; Olanzapine; Piperazines; Quality of Life; Schizophrenia; Statistics as Topic; Thiazoles; Verbal Learning; Young Adult | 2010 |
Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Size; Body Weight; Diagnostic and Statistical Manual of Mental Disorders; Female; Hip; Humans; Hyperprolactinemia; Liver Function Tests; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Thiazoles; Treatment Outcome; Waist Circumference; Wakefulness; Young Adult | 2010 |
A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Haloperidol; Humans; Piperazines; Psychiatric Status Rating Scales; Quality of Life; Remission Induction; Schizophrenia; Schizophrenic Psychology; Thiazoles; Time Factors; Treatment Outcome | 2010 |
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chi-Square Distribution; Dibenzothiazepines; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Movement Disorders; Olanzapine; Perphenazine; Piperazines; Proportional Hazards Models; Psychiatric Status Rating Scales; Quetiapine Fumarate; Risperidone; Schizophrenia; Severity of Illness Index; Thiazoles; Treatment Outcome | 2011 |
Effects on cognitive functioning after olanzapine-ziprasidone crossover in recent-onset schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Benzodiazepines; Cognition; Cross-Over Studies; Double-Blind Method; Drug Substitution; Female; Follow-Up Studies; Humans; Male; Neuropsychological Tests; Olanzapine; Piperazines; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome; Young Adult | 2010 |
Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC).
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cause of Death; Cross-Sectional Studies; Death, Sudden, Cardiac; Diabetic Ketoacidosis; Female; Hospitalization; Humans; Incidence; Kaplan-Meier Estimate; Long QT Syndrome; Male; Middle Aged; Myocardial Infarction; Olanzapine; Piperazines; Product Surveillance, Postmarketing; Prospective Studies; Risk; Schizophrenia; Suicide; Thiazoles | 2011 |
An unblinded comparison of the clinical and cognitive effects of switching from first-generation antipsychotics to aripiprazole, perospirone or olanzapine in patients with chronic schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Attention; Benzodiazepines; Chronic Disease; Cognition Disorders; Dose-Response Relationship, Drug; Drug Substitution; Executive Function; Female; Humans; Isoindoles; Longitudinal Studies; Male; Memory; Middle Aged; Neuropsychological Tests; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Single-Blind Method; Thiazoles; Time Factors; Verbal Learning | 2011 |
Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Female; Humans; Isoindoles; Lurasidone Hydrochloride; Male; Middle Aged; Neuropsychological Tests; Psychiatric Status Rating Scales; Psychometrics; Reproducibility of Results; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles | 2011 |
Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controll
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Cholesterol; Drug Monitoring; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Quinolones; Schizophrenia; Thiazoles; Time Factors; Triglycerides; Weight Gain | 2010 |
Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Schizophrenia; Thiazoles; Young Adult | 2011 |
Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cognition Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Interview, Psychological; Isoindoles; Lurasidone Hydrochloride; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Thiazoles; Young Adult | 2011 |
Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Blood Glucose; Body Weight; Cholesterol; Cognition; Dibenzothiazepines; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Outpatients; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Schizophrenia; Thiazoles; Treatment Outcome; Triglycerides; Young Adult | 2011 |
Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Isoindoles; Lurasidone Hydrochloride; Male; Middle Aged; Olanzapine; Patient Admission; Psychiatric Status Rating Scales; Schizophrenia; Thiazoles; Treatment Outcome | 2011 |
Transition from ziprasidone im to oral formulation in agitated patients with acute exacerbation of schizophrenia: an open trial.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Schizophrenia; Thiazoles | 2011 |
Methodological challenges in the coding and adjudication of sudden deaths in a large simple trial with observational follow-up: the ziprasidone observational study of cardiac outcomes (ZODIAC).
Topics: Antipsychotic Agents; Benzodiazepines; Cause of Death; Clinical Coding; Death, Sudden; Death, Sudden, Cardiac; Endpoint Determination; Follow-Up Studies; Heart; Humans; Incidence; International Classification of Diseases; Olanzapine; Piperazines; Product Surveillance, Postmarketing; Research Design; Risk; Schizophrenia; Sensitivity and Specificity; Surveys and Questionnaires; Thiazoles; Time Factors; United States; United States Food and Drug Administration | 2011 |
Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).
Topics: Adult; Aggression; Amisulpride; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Haloperidol; Hostility; Humans; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Schizophrenia; Schizophrenic Psychology; Sulpiride; Thiazoles; Treatment Outcome | 2011 |
Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Body Weight; Cholesterol; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Humans; Isoindoles; Lurasidone Hydrochloride; Male; Middle Aged; Outpatients; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Thiazoles; Time Factors; Treatment Outcome; Triglycerides; Young Adult | 2011 |
The lack of effect of ziprasidone on platelet serotonin concentration in schizophrenic patients.
Topics: Antipsychotic Agents; Blood Platelets; Dose-Response Relationship, Drug; Female; Humans; Male; Piperazines; Psychotic Disorders; Schizophrenia; Serotonin; Serotonin Antagonists; Thiazoles; Time Factors | 2012 |
Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Labeling; Female; Haloperidol; Humans; Isoxazoles; Male; Middle Aged; Piperazines; Piperidines; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome; Young Adult | 2012 |
Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Atherosclerosis; Bipolar Disorder; Cohort Studies; Diagnostic and Statistical Manual of Mental Disorders; Drug Monitoring; Dyslipidemias; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; North America; Patient Dropouts; Piperazines; Psychotic Disorders; Quinolones; Risk Factors; Schizophrenia; Severity of Illness Index; Thiazoles; Weight Loss | 2012 |
Efficacy and tolerability of ziprasidone vs. olanzapine in naive first-episode schizophrenia: a 6-week, randomized, open-label, flexible-dose study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comparative Effectiveness Research; Dose-Response Relationship, Drug; Drug Monitoring; Episode of Care; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Thiazoles; Time Factors; Treatment Outcome; Weight Gain | 2012 |
Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Dopamine D2 Receptor Antagonists; Female; Humans; Linear Models; Male; Middle Aged; Olanzapine; Piperazines; Receptors, Dopamine D2; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Young Adult | 2013 |
Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study.
Topics: Adult; Ambulatory Care; Analysis of Variance; Antipsychotic Agents; Croatia; Double-Blind Method; Female; Humans; Isoindoles; Israel; Kaplan-Meier Estimate; Lurasidone Hydrochloride; Male; Middle Aged; Proportional Hazards Models; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology; South Africa; South America; Thailand; Thiazoles; Time Factors; Treatment Outcome; United States | 2012 |
Efficacy and tolerability of switching to ziprasidone in italian patients with acute exacerbation of schizophrenia: an open-label trial.
Topics: Adult; Antipsychotic Agents; Female; Humans; Long QT Syndrome; Male; Middle Aged; Patient Preference; Piperazines; Psychiatric Status Rating Scales; Schizophrenia; Thiazoles | 2012 |
Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Dibenzothiazepines; Female; Haloperidol; Humans; Male; Neuropsychological Tests; Olanzapine; Piperazines; Psychomotor Disorders; Psychotic Disorders; Quetiapine Fumarate; Schizophrenia; Schizophrenic Psychology; Sulpiride; Thiazoles; Treatment Outcome; Young Adult | 2013 |
Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cholesterol; Dibenzothiazepines; Disorders of Excessive Somnolence; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Isoindoles; Likelihood Functions; Lurasidone Hydrochloride; Male; Medication Adherence; Nausea; Numbers Needed To Treat; Olanzapine; Psychiatric Status Rating Scales; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Research Design; Schizophrenia; Thiazoles; Treatment Outcome; Triglycerides; Weight Gain | 2012 |
Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Brief Psychiatric Rating Scale; Double-Blind Method; Female; Humans; Isoindoles; Lurasidone Hydrochloride; Male; Middle Aged; Schizophrenia; Schizophrenic Psychology; Single-Blind Method; Thiazoles; Young Adult | 2013 |
Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Weight; Female; Glucose; Humans; Insulin; Lipid Metabolism; Male; Middle Aged; Olanzapine; Piperazines; Schizophrenia; Thiazoles; Young Adult | 2013 |
One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Humans; Male; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2012 |
A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Female; Humans; Isoindoles; Japan; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Severity of Illness Index; Thiazoles; Treatment Outcome | 2013 |
Early prediction of clinical and functional outcome in schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition; Cognition Disorders; Double-Blind Method; Drug Monitoring; Drug Resistance; Female; Follow-Up Studies; Humans; Male; Middle Aged; Models, Biological; Olanzapine; Patient Dropouts; Piperazines; Prognosis; Psychiatric Status Rating Scales; Schizophrenia; Thiazoles; Weight Gain | 2013 |
Lessons learned in the conduct of a global, large simple trial of treatments indicated for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Cause of Death; Humans; International Cooperation; Longitudinal Studies; Lost to Follow-Up; Olanzapine; Patient Selection; Piperazines; Research Design; Schizophrenia; Thiazoles | 2013 |
Long-term safety of ziprasidone in schizophrenic patients: an open trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Electrocardiography; Female; Humans; Male; Middle Aged; Piperazines; Schizophrenia; Thiazoles | 2012 |
Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Substitution; Female; Humans; India; Isoxazoles; Longitudinal Studies; Male; Middle Aged; Piperazines; Piperidines; Psychiatric Status Rating Scales; Schizophrenia; Thiazoles; Time Factors; Treatment Outcome; United States; Young Adult | 2013 |
A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Recurrence; Schizophrenia; Thiazoles; Time Factors; Treatment Outcome | 2002 |
Ziprasidone augmentation of clozapine in 11 patients.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome; Weight Gain | 2003 |
Prolactin levels in schizophrenic patients receiving perospirone in comparison to risperidone.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Humans; Indoles; Isoindoles; Male; Middle Aged; Prolactin; Risperidone; Schizophrenia; Thiazoles | 2003 |
Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.
Topics: Adolescent; Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Cross-Over Studies; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Pirenzepine; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Thiazoles; Treatment Outcome | 2003 |
Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition; Double-Blind Method; Female; Hospitalization; Humans; Male; Memory; Middle Aged; Olanzapine; Piperazines; Psychotic Disorders; Schizophrenia; Thiazoles | 2004 |
Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Weight; Female; Health Status Indicators; Humans; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Psychotic Disorders; Risperidone; Schizophrenia; Thiazoles; Withholding Treatment | 2003 |
Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia.
Topics: Adolescent; Adult; Ambulatory Care; Arousal; Attention; Benzodiazepines; Cognition; Drug Administration Schedule; Drug Tolerance; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Olanzapine; Piperazines; Risperidone; Schizophrenia; Thiazoles; Verbal Behavior | 2004 |
A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.
Topics: Adult; Antipsychotic Agents; Brain; Corpus Striatum; Drug Administration Schedule; Female; Humans; Male; Piperazines; Psychotic Disorders; Pyrimidinones; Raclopride; Receptors, Dopamine D2; Receptors, Serotonin, 5-HT2; Schizophrenia; Thiazoles; Tomography, Emission-Computed | 2004 |
Steady-state pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response.
Topics: Adult; Aged; Antipsychotic Agents; Area Under Curve; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; Humans; Immunoenzyme Techniques; Indoles; Isoindoles; Male; Middle Aged; Prolactin; Schizophrenia; Thiazoles; Time Factors | 2004 |
Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Lorazepam; Male; Metabolic Syndrome; Middle Aged; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Thiazoles; Treatment Outcome; Weight Gain | 2004 |
Effects of changing from typical to atypical antipsychotic drugs on subjective sleep quality in patients with schizophrenia in a Japanese population.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Drug Administration Schedule; Female; Health Status; Hospitalization; Humans; Indoles; Isoindoles; Japan; Male; Middle Aged; Olanzapine; Psychiatric Status Rating Scales; Quetiapine Fumarate; Regression Analysis; Risperidone; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Sleep; Thiazoles | 2004 |
Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Double-Blind Method; Female; Follow-Up Studies; Humans; Hyperprolactinemia; Male; Patient Dropouts; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Sexual Dysfunctions, Psychological; Sleep Initiation and Maintenance Disorders; Thiazoles; Treatment Outcome | 2004 |
Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study.
Topics: Acute Disease; Administration, Oral; Adult; Affective Disorders, Psychotic; Brief Psychiatric Rating Scale; Demography; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Manifest Anxiety Scale; Piperazines; Schizophrenia; Severity of Illness Index; Thiazoles; Time Factors; Treatment Outcome; Withholding Treatment | 2005 |
Influence of aging on the improvement of subjective sleep quality by atypical antipsychotic drugs in patients with schizophrenia: comparison of middle-aged and older adults.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Humans; Indoles; Isoindoles; Male; Middle Aged; Olanzapine; Polysomnography; Psychiatric Status Rating Scales; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Sleep Initiation and Maintenance Disorders; Sleep Stages; Thiazoles | 2005 |
Cerebral cortical gray expansion associated with two second-generation antipsychotics.
Topics: Adult; Antipsychotic Agents; Atrophy; Cerebral Cortex; Cognition Disorders; Female; Follow-Up Studies; Haloperidol; Humans; Magnetic Resonance Imaging; Male; Nerve Growth Factors; Piperazines; Psychiatric Status Rating Scales; Quality of Life; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome | 2005 |
Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia.
Topics: Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Double-Blind Method; Drug Administration Schedule; Follow-Up Studies; Humans; Obesity; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Thiazoles; Treatment Outcome; Weight Gain | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Method; Female; Humans; Lipids; Male; Olanzapine; Patient Compliance; Perphenazine; Piperazines; Proportional Hazards Models; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome; Weight Gain | 2005 |
Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia.
Topics: Adult; Age of Onset; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Blood Glucose; Double-Blind Method; Drug Administration Schedule; Fasting; Female; Humans; Lipids; Male; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Quality of Life; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Thiazoles; Treatment Outcome | 2005 |
Perospirone in the treatment of schizophrenia: effect on verbal memory organization.
Topics: Adult; Aged; Antipsychotic Agents; Female; Humans; Indoles; Isoindoles; Male; Memory; Middle Aged; Neuropsychological Tests; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Statistics, Nonparametric; Thiazoles; Verbal Learning | 2006 |
Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Chlorpromazine; Double-Blind Method; Drug Resistance; Female; Haloperidol; Humans; Male; Piperazines; Prolactin; Schizophrenia; Thiazoles; Time Factors | 2006 |
Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Olanzapine; Patient Admission; Piperazines; Psychometrics; Psychotic Disorders; Schizophrenia; Thiazoles | 2006 |
Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Amisulpride; Antipsychotic Agents; Behavioral Symptoms; Double-Blind Method; Female; Hospitalization; Humans; Ketones; Male; Middle Aged; Movement Disorders; Piperazines; Psychiatric Status Rating Scales; Schizophrenia; Sulpiride; Thiazoles; Time Factors; Treatment Outcome; Weight Gain; Weight Loss | 2006 |
Effect of initial ziprasidone dose on length of therapy in schizophrenia.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperazines; Proportional Hazards Models; Psychiatric Status Rating Scales; Retrospective Studies; Risk; Schizophrenia; Thiazoles; Time Factors; Treatment Outcome | 2006 |
Effect of initial ziprasidone dose on treatment persistence in schizophrenia.
Topics: Adult; Antipsychotic Agents; Chi-Square Distribution; Demography; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Proportional Hazards Models; Psychiatric Status Rating Scales; Retrospective Studies; Schizophrenia; Sensitivity and Specificity; Thiazoles; Treatment Outcome | 2006 |
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Cross-Over Studies; Dibenzothiazepines; Drug Monitoring; Drug Resistance; Eosinophilia; Female; Follow-Up Studies; Humans; Male; Olanzapine; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome | 2006 |
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Weight; Chronic Disease; Cross-Over Studies; Dibenzothiazepines; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Olanzapine; Patient Dropouts; Piperazines; Proportional Hazards Models; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Survival Analysis; Thiazoles; Time Factors; Treatment Outcome | 2006 |
A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms.
Topics: Antipsychotic Agents; Benzodiazepines; Depression; Glycated Hemoglobin; Humans; Olanzapine; Patient Dropouts; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Thiazoles; Treatment Outcome; Triglycerides; United States; Weight Gain | 2006 |
Efficacy of ziprasidone against hostility in schizophrenia: Post hoc analysis of randomized, open-label study data.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Female; Haloperidol; Hospitalization; Hostility; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome | 2006 |
The effect of perospirone on auditory P300 in schizophrenia: a preliminary study.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Data Interpretation, Statistical; Electrophysiology; Event-Related Potentials, P300; Evoked Potentials, Auditory; Female; Humans; Indoles; Isoindoles; Male; Middle Aged; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Thiazoles | 2006 |
Intramuscular ziprasidone treatment of acute psychotic agitation in elderly patients with schizophrenia.
Topics: Acute Disease; Aged; Aged, 80 and over; Antipsychotic Agents; Drug Administration Schedule; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Psychomotor Agitation; Psychotic Disorders; Schizophrenia; Thiazoles | 2006 |
Ziprasidone-induced cognitive enhancement in schizophrenia: specificity or pseudospecificity?
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Brief Psychiatric Rating Scale; Cognition; Cognition Disorders; Female; Humans; Male; Memory; Middle Aged; Neuropsychological Tests; Piperazines; Schizophrenia; Severity of Illness Index; Thiazoles | 2006 |
Early changes of plasma lipids during treatment with atypical antipsychotics.
Topics: Adolescent; Adult; Aged; Amisulpride; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight; Cholesterol; Clozapine; Humans; Lipids; Middle Aged; Olanzapine; Piperazines; Prospective Studies; Schizophrenia; Sulpiride; Thiazoles; Time Factors; Triglycerides | 2006 |
The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone.
Topics: Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Health Status; Humans; Longitudinal Studies; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Quality of Life; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome | 2006 |
[Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
Topics: Adult; Aged; Antipsychotic Agents; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Thiazoles; Treatment Outcome | 2006 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenzothiazepines; Follow-Up Studies; Health Status; Humans; National Institute of Mental Health (U.S.); Olanzapine; Patient Dropouts; Perphenazine; Piperazines; Quality of Life; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Social Adjustment; Thiazoles; Treatment Outcome; United States | 2007 |
Ziprasidone outcome and tolerability: a practical clinical trial with plasma drug levels.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Body Weight; Chromatography, High Pressure Liquid; Electrocardiography; Female; Humans; Male; Middle Aged; Piperazines; Schizophrenia; Thiazoles | 2007 |
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Cohort Studies; Dibenzothiazepines; Double-Blind Method; Female; Humans; Male; Neuropsychological Tests; Olanzapine; Perphenazine; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome | 2007 |
Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
Topics: Adult; Antipsychotic Agents; Body Weight; Chronic Disease; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Schizophrenia; Thiazoles | 2007 |
Cost-effectiveness analysis of ziprasidone versus haloperidol in sequential intramuscular/oral treatment of exacerbation of schizophrenia: economic subanalysis of the ZIMO trial.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Cost of Illness; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; Haloperidol; Hospital Costs; Humans; Injections, Intramuscular; Length of Stay; Male; Piperazines; Quality of Life; Research Design; Schizophrenia; Spain; Thiazoles; Treatment Outcome | 2007 |
Ziprasidone in treatment-resistant schizophrenia: a 52-week, open-label continuation study.
Topics: Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Chlorpromazine; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Multiple; Female; Humans; Male; Piperazines; Schizophrenia; Thiazoles; Treatment Outcome | 2007 |
Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study.
Topics: Acute Disease; Adult; Affective Disorders, Psychotic; Antipsychotic Agents; Aripiprazole; Blood Glucose; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Dyspepsia; Electrocardiography; Fasting; Humans; Lipids; Nausea; Piperazines; Prolactin; Quinolones; Schizophrenia; Severity of Illness Index; Thiazoles; Time Factors; Treatment Outcome; Weight Loss | 2007 |
Clinical implications of the CATIE schizophrenia trials: day-to-day management lessons for Australasian psychiatrists.
Topics: Antipsychotic Agents; Australia; Benzodiazepines; Dibenzothiazepines; Double-Blind Method; Humans; Olanzapine; Perphenazine; Piperazines; Psychiatry; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Time Factors | 2007 |
A randomized double-blind comparison of ziprasidone vs. clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment.
Topics: Adult; Antipsychotic Agents; Clozapine; Cognition Disorders; Double-Blind Method; Drug Resistance; Drug Tolerance; Female; Humans; Italy; Male; Memory Disorders; Neuropsychological Tests; Piperazines; Placebos; Schizophrenia; Schizophrenic Psychology; Thiazoles; Trail Making Test; Treatment Outcome | 2008 |
Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Borderline Personality Disorder; Comorbidity; Depressive Disorder, Major; Disruptive, Impulse Control, and Conduct Disorders; Double-Blind Method; Humans; Middle Aged; Neurocognitive Disorders; Piperazines; Psychoses, Substance-Induced; Schizophrenia; Substance-Related Disorders; Surveys and Questionnaires; Thiazoles | 2008 |
The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): design and baseline subject characteristics.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Dyslipidemias; Female; Glycated Hemoglobin; Humans; Hypertension; Long QT Syndrome; Male; Observation; Piperazines; Prevalence; Research Design; Schizophrenia; Severity of Illness Index; Surveys and Questionnaires; Thiazoles; Triglycerides | 2008 |
Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Female; Humans; Isoxazoles; Male; Middle Aged; Piperazines; Piperidines; Prospective Studies; Schizophrenia; Thiazoles; Treatment Outcome | 2008 |
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Haloperidol; Humans; Linear Models; Male; Olanzapine; Patient Compliance; Piperazines; Proportional Hazards Models; Quetiapine Fumarate; Schizophrenia; Sulpiride; Thiazoles; Treatment Outcome | 2008 |
What CATIE found: results from the schizophrenia trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Dibenzothiazepines; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Male; Middle Aged; Olanzapine; Perphenazine; Piperazines; Psychology; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles | 2008 |
Pramipexole as adjunct to haloperidol in schizophrenia. Safety and efficacy.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzothiazoles; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Middle Aged; Pramipexole; Prospective Studies; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Thiazoles | 1997 |
An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Haloperidol; Hospitalization; Humans; Male; Middle Aged; Neurologic Examination; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome | 1998 |
Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Schizophrenia; Thiazoles | 1998 |
Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Thiazoles | 1999 |
Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients.
Topics: Antipsychotic Agents; Area Under Curve; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Injections, Intramuscular; Male; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Thiazoles; Treatment Outcome | 2001 |
The apparent effects of ziprasidone on plasma lipids and glucose.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Blood Glucose; Body Mass Index; Body Weight; Cholesterol; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lipids; Male; Outcome Assessment, Health Care; Piperazines; Psychotic Disorders; Schizophrenia; Thiazoles; Triglycerides | 2001 |
A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Male; Middle Aged; Nausea; Piperazines; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Sleep Initiation and Maintenance Disorders; Thiazoles; Treatment Outcome; Vomiting | 2002 |
170 other study(ies) available for thiazoles and Schizophrenia
| Article | Year |
|---|---|
The relation between second-generation antipsychotics and laxative use in elderly patients with schizophrenia.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Constipation; Female; Humans; Laxatives; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles | 2022 |
The safety and efficacy of sequential intramuscular/oral ziprasidone treatment of acute episode in patients with schizophrenia: a multicenter, open-labeled study.
Topics: Antipsychotic Agents; Humans; Injections, Intramuscular; Piperazines; Psychiatric Status Rating Scales; Schizophrenia; Thiazoles; Treatment Outcome | 2023 |
Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Female; Health Care Costs; Hospitalization; Humans; Lurasidone Hydrochloride; Male; Medicaid; Medicare; Middle Aged; Olanzapine; Paliperidone Palmitate; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles; Thiophenes; United States | 2020 |
When Green Becomes Mean: Green Tea Extract Reduces Ziprasidone's Effect and Causes Psychosis.
Topics: Antipsychotic Agents; Food-Drug Interactions; Humans; Male; Piperazines; Psychoses, Substance-Induced; Schizophrenia; Tea; Thiazoles; Young Adult | 2020 |
[Electroconvulsive Therapy - A beneficial and well tolerated therapy in children and adolescents with schizophrenia].
Topics: Adolescent; Catatonia; Child; Clozapine; Combined Modality Therapy; Electroconvulsive Therapy; Humans; Piperazines; Schizophrenia; Thiazoles; Treatment Outcome | 2020 |
Parenteral Sustained Release Lipid Phase-Transition System of Ziprasidone: Fabrication and Evaluation for Schizophrenia Therapy.
Topics: Animals; Antipsychotic Agents; Delayed-Action Preparations; Lipids; Male; Piperazines; Rats; Rats, Sprague-Dawley; Schizophrenia; Thiazoles | 2020 |
Identification and Quantification of Antipsychotics in Blood Samples by LC-MS-MS: Case Reports and Data from Three Years of Routine Analysis.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chromatography, Liquid; Clozapine; Dibenzothiazepines; Female; Forensic Toxicology; Humans; Male; Olanzapine; Paliperidone Palmitate; Piperazines; Quetiapine Fumarate; Retrospective Studies; Risperidone; Schizophrenia; Substance Abuse Detection; Suicide; Sulpiride; Tandem Mass Spectrometry; Thiazoles | 2020 |
Association of C-reactive protein and metabolic risk with cognitive effects of lurasidone in patients with schizophrenia.
Topics: Antipsychotic Agents; C-Reactive Protein; Cognition; Double-Blind Method; Humans; Isoindoles; Lurasidone Hydrochloride; Psychiatric Status Rating Scales; Schizophrenia; Thiazoles; Treatment Outcome | 2020 |
The side effect profile of Clozapine in real world data of three large mental health hospitals.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Databases, Factual; Female; Hospitals, Psychiatric; Humans; Infant; Male; Middle Aged; Olanzapine; Piperazines; Risperidone; Schizophrenia; Thiazoles; Weight Gain | 2020 |
Effects of haloperidol, olanzapine, ziprasidone, and PHA-543613 on spatial learning and memory in the Morris water maze test in naïve and MK-801-treated mice.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heterocyclic; Disease Models, Animal; Haloperidol; Male; Maze Learning; Memory; Mice; Mice, Inbred C57BL; Olanzapine; Piperazines; Quinuclidines; Schizophrenia; Spatial Learning; Thiazoles; Treatment Outcome | 2017 |
Design and Synthesis of Novel Positive Allosteric Modulators of α7 Nicotinic Acetylcholine Receptors with the Ability To Rescue Auditory Gating Deficit in Mice.
Topics: Acetylcholine; Administration, Oral; Allosteric Regulation; alpha7 Nicotinic Acetylcholine Receptor; Animals; Blood-Brain Barrier; Disease Models, Animal; Drug Design; Evoked Potentials; Half-Life; Humans; Mice; Oocysts; Rats; Schizophrenia; Structure-Activity Relationship; Thiazoles; Xenopus laevis | 2019 |
Pharmacological characterization of JWX-A0108 as a novel type I positive allosteric modulator of α7 nAChR that can reverse acoustic gating deficits in a mouse prepulse inhibition model.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Dizocilpine Maleate; Hippocampus; Humans; Interneurons; Locomotion; Male; Maze Learning; Memory Disorders; Mice, Inbred C57BL; Nootropic Agents; Prepulse Inhibition; Rats, Sprague-Dawley; Schizophrenia; Sensory Gating; Synaptic Transmission; Thiazoles; Xenopus | 2019 |
Perospirone normalized P300 and cognitive function in a case of early psychosis.
Topics: Adolescent; Antipsychotic Agents; Cognition Disorders; Event-Related Potentials, P300; Humans; Isoindoles; Male; Schizophrenia; Thiazoles; Treatment Outcome | 2013 |
A case of schizophrenia with meige syndrome induced by perospirone successfully treated with biperiden.
Topics: Adult; Antiparkinson Agents; Antipsychotic Agents; Biperiden; Female; Humans; Isoindoles; Lymphedema; Schizophrenia; Thiazoles | 2013 |
Comparison of outcomes for African Americans, Hispanics, and Non-Hispanic Whites in the CATIE study.
Topics: Adult; Antipsychotic Agents; Black or African American; Clinical Trials as Topic; Female; Hispanic or Latino; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Patient Dropouts; Perphenazine; Piperazines; Schizophrenia; Thiazoles; United States; White People; Young Adult | 2013 |
Immediate intervention: life-long success.
Topics: Adult; Antipsychotic Agents; Cognitive Behavioral Therapy; Female; Humans; Piperazines; Schizophrenia; Thiazoles; Treatment Outcome; Trifluoperazine | 2014 |
Short-term remission in schizophrenia as a combination of several outcome measures.
Topics: Adolescent; Adult; Antipsychotic Agents; Body Mass Index; Cognition Disorders; Female; Humans; Logistic Models; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines; Psychiatric Status Rating Scales; Recurrence; Schizophrenia; Thiazoles; Treatment Outcome; Young Adult | 2013 |
Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Clinical Trials as Topic; Clozapine; Comorbidity; Cost-Benefit Analysis; Diabetes Mellitus; Hospitalization; Humans; Isoindoles; Lurasidone Hydrochloride; Markov Chains; Models, Economic; Outcome Assessment, Health Care; Piperazines; Quinolones; Recurrence; Schizophrenia; Thiazoles; United States | 2013 |
Switching to ziprasidone in the clinical practice setting: an open-label study.
Topics: Adult; Antipsychotic Agents; Body Weight; Brief Psychiatric Rating Scale; Drug Substitution; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Psychometrics; Psychotic Disorders; Quality of Life; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome | 2013 |
From the editor-in-chief's desk.
Topics: Antipsychotic Agents; Humans; Piperazines; Schizophrenia; Thiazoles | 2013 |
Effects of antipsychotic drugs on insight in schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Awareness; Benzodiazepines; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Thiazoles | 2014 |
Parenteral thermo-sensitive organogel for schizophrenia therapy, in vitro and in vivo evaluation.
Topics: Animals; Antipsychotic Agents; Coumarins; Drug Delivery Systems; Fatty Acids; Gels; Isoxazoles; Male; Mice, Nude; Paliperidone Palmitate; Phase Transition; Pyrimidines; Rats, Sprague-Dawley; Schizophrenia; Soybean Oil; Thiazoles; Transition Temperature; Viscosity | 2014 |
Comparison of health services use associated with ziprasidone and olanzapine among schizophrenia and bipolar disorder patients in the USA.
Topics: Adult; Ambulatory Care; Benzodiazepines; Bipolar Disorder; Emergency Service, Hospital; Female; Health Care Costs; Health Services; Humans; Male; Middle Aged; Olanzapine; Piperazines; Schizophrenia; Thiazoles; United States | 2014 |
Cost-effectiveness of second-generation antipsychotics for the treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cost-Benefit Analysis; Dibenzothiazepines; Drug Therapy, Combination; Female; Humans; Male; Markov Chains; Olanzapine; Piperazines; Quality-Adjusted Life Years; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles | 2014 |
Dried blood spot testing: a novel approach for the therapeutic drug monitoring of ziprasidone-treated patients.
Topics: Blood Specimen Collection; Chromatography, Liquid; Dried Blood Spot Testing; Drug Monitoring; Humans; Piperazines; Schizophrenia; Tandem Mass Spectrometry; Thiazoles | 2014 |
Treatment with Ziprasidone for schizophrenia patients with OCD.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Schizophrenia; Thiazoles; Treatment Outcome; Young Adult | 2014 |
Update on putative novel antipsychotics.
Topics: Antipsychotic Agents; Brain Injuries; Clozapine; Cognition Disorders; Drug Therapy, Combination; Employment, Supported; Humans; Piperazines; Schizophrenia; Thiazoles | 2014 |
Lurasidone suppresses rapid eye movement sleep and improves sleep quality in rats.
Topics: Animals; Antipsychotic Agents; Electroencephalography; Isoindoles; Lurasidone Hydrochloride; Male; Rats, Wistar; Schizophrenia; Sleep Wake Disorders; Sleep, REM; Thiazoles; Wakefulness | 2014 |
Understanding responder neurobiology in schizophrenia using a quantitative systems pharmacology model: application to iloperidone.
Topics: Antipsychotic Agents; Computer Simulation; Genotype; Humans; Isoxazoles; Models, Biological; Molecular Targeted Therapy; Neurobiology; Pharmacogenetics; Piperazines; Piperidines; Schizophrenia; Thiazoles | 2015 |
Transient agranulocytosis associated with ziprasidone in a 45-year-old man on hemodialysis.
Topics: Agranulocytosis; Antipsychotic Agents; Humans; Kidney Failure, Chronic; Male; Middle Aged; Piperazines; Renal Dialysis; Schizophrenia; Thiazoles | 2015 |
Did FDA Decisionmaking Affect Anti-Psychotic Drug Prescribing in Children?: A Time-Trend Analysis.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Child; Decision Making; Drug Approval; Drug Prescriptions; Female; Humans; Male; Middle Aged; Olanzapine; Pediatrics; Piperazines; Quetiapine Fumarate; Schizophrenia; Thiazoles; United States; United States Food and Drug Administration | 2016 |
Development of a Web-Based Clinical Decision Support System for Drug Prescription: Non-Interventional Naturalistic Description of the Antipsychotic Prescription Patterns in 4345 Outpatients and Future Applications.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Community Mental Health Centers; Decision Support Systems, Clinical; Drug Prescriptions; Female; Humans; Inappropriate Prescribing; Internet; Male; Middle Aged; Outpatients; Paliperidone Palmitate; Piperazines; Schizophrenia; Thiazoles; Young Adult | 2016 |
Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Humans; Insurance Claim Review; Lurasidone Hydrochloride; Male; Medicaid; Medication Adherence; Middle Aged; Olanzapine; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; United States | 2017 |
A neuroimaging study of emotion-cognition interaction in schizophrenia: the effect of ziprasidone treatment.
Topics: Adolescent; Adult; Antipsychotic Agents; Brain Mapping; Cognition; Emotions; Female; Gray Matter; Humans; Magnetic Resonance Imaging; Male; Neuroimaging; Piperazines; Prefrontal Cortex; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Thiazoles; White Matter; Young Adult | 2017 |
Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Patient Compliance; Piperazines; Quality of Life; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles | 2008 |
Clinical experiences and clinical trials.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dyskinesia, Drug-Induced; Humans; Olanzapine; Perphenazine; Piperazines; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome | 2008 |
Repeated acute dystonia following administration of amisulpride and ziprasidone in a patient with iron deficiency.
Topics: Adolescent; Amisulpride; Anemia, Iron-Deficiency; Antipsychotic Agents; Dibenzothiazepines; Dystonia; Female; Hemoglobins; Humans; Piperazines; Quetiapine Fumarate; Schizophrenia; Sulpiride; Thiazoles | 2008 |
Haloperidol (but not ziprasidone) withdrawal potentiates sensitization to the hyperlocomotor effect of cocaine in mice.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Cocaine; Cocaine-Related Disorders; Haloperidol; Humans; Male; Mice; Motor Activity; Piperazines; Schizophrenia; Substance Withdrawal Syndrome; Thiazoles | 2008 |
Ziprasidone-associated mania in Korean schizophrenic patient.
Topics: Adult; Antipsychotic Agents; Asian People; Bipolar Disorder; Humans; Korea; Male; Piperazines; Schizophrenia; Schizophrenic Psychology; Thiazoles | 2008 |
Weight effects associated with antipsychotics: a comprehensive database analysis.
Topics: Antipsychotic Agents; Databases, Bibliographic; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Piperazines; Randomized Controlled Trials as Topic; Schizophrenia; Thiazoles; Time Factors; Weight Gain | 2009 |
Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles; Time Factors; Treatment Outcome | 2009 |
Targeting cognition in schizophrenia research: from etiology to treatment.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Cognition; Cognition Disorders; Dibenzothiazepines; Drug Administration Schedule; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Reaction Time; Schizophrenia; Sulpiride; Thiazoles | 2009 |
P wave and QT changes among inpatients with schizophrenia after parenteral ziprasidone administration.
Topics: Adult; Antipsychotic Agents; Atrial Fibrillation; Electrocardiography; Female; Humans; Male; Middle Aged; Piperazines; Schizophrenia; Thiazoles | 2009 |
How dosing of ziprasidone in a state hospital system differs from product labeling.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Utilization; Female; Hospitalization; Hospitals, Psychiatric; Hospitals, State; Humans; Male; Piperazines; Prescription Drugs; Product Labeling; Psychotic Disorders; Quetiapine Fumarate; Schizophrenia; Thiazoles; Treatment Outcome | 2009 |
FDA panel OKs 3 antipsychotic drugs for pediatric use, cautions against overuse.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Child; Dibenzothiazepines; Drug Approval; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Schizophrenia; Thiazoles; United States; United States Food and Drug Administration | 2009 |
Ziprasidone-related oculogyric crisis in an adult.
Topics: Adult; Antipsychotic Agents; Clonazepam; Dyskinesia, Drug-Induced; Electroencephalography; Female; GABA Modulators; Humans; Ocular Motility Disorders; Oculomotor Muscles; Piperazines; Schizophrenia; Thiazoles | 2009 |
Pregnancy and atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Drug Therapy, Combination; Female; Fluphenazine; Humans; Infant, Newborn; Piperazines; Pregnancy; Pregnancy Complications; Recurrence; Schizophrenia; Thiazoles | 2009 |
Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Topic; Databases, Factual; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; International Classification of Diseases; Male; Middle Aged; Piperazines; Probability; Propensity Score; Proportional Hazards Models; Psychiatric Status Rating Scales; Retrospective Studies; Schizophrenia; Thiazoles; Time Factors; Treatment Outcome | 2009 |
Ziprasidone as a possible cause of cleft palate in a newborn.
Topics: Adult; Antipsychotic Agents; Cleft Palate; Dose-Response Relationship, Drug; Female; Humans; Infant, Newborn; Piperazines; Pregnancy; Pregnancy Complications; Risk Factors; Schizophrenia; Thiazoles; Ultrasonography, Prenatal | 2010 |
Comparison of short-acting intramuscular antipsychotic medication: impact on length of stay and cost.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cohort Studies; Drug Costs; Female; Haloperidol; Humans; Injections, Intramuscular; Length of Stay; Male; Middle Aged; Olanzapine; Piperazines; Psychomotor Agitation; Quinolones; Retrospective Studies; Schizophrenia; Thiazoles | 2011 |
Dopamine D2 receptor occupancy by perospirone: a positron emission tomography study in patients with schizophrenia and healthy subjects.
Topics: Adult; Antipsychotic Agents; Binding, Competitive; Brain; Case-Control Studies; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Female; Humans; Isoindoles; Magnetic Resonance Imaging; Male; Positron-Emission Tomography; Raclopride; Receptors, Dopamine D2; Schizophrenia; Thiazoles; Time Factors | 2010 |
The wide variability of perospirone metabolism and the effect of perospirone on prolactin in psychiatric patients.
Topics: Adult; Aged; Antipsychotic Agents; Chromatography, High Pressure Liquid; Female; Humans; Immunoenzyme Techniques; Individuality; Indoles; Isoindoles; Male; Middle Aged; Prolactin; Schizophrenia; Thiazoles | 2010 |
Prolactin fluctuation over the course of a day during treatments with three atypical antipsychotics in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Circadian Rhythm; Drug Administration Schedule; Drug Monitoring; Female; Humans; Hyperprolactinemia; Isoindoles; Male; Middle Aged; Olanzapine; Prolactin; Risperidone; Schizophrenia; Thiazoles; Time Factors; Treatment Outcome | 2010 |
Increased striatal dopamine transporter levels, as indicated by a DAT scan, induced by ziprasidone in association to improvement of tardive dyskinesia--a case report.
Topics: Antipsychotic Agents; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Humans; Male; Middle Aged; Piperazines; Schizophrenia; Thiazoles; Treatment Outcome | 2010 |
How sequential studies inform drug development: evaluating the effect of food intake on optimal bioavailability of ziprasidone.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Biological Availability; Biomedical Research; Bipolar Disorder; Dietary Fats; Dose-Response Relationship, Drug; Drug Evaluation; Drug Monitoring; Drugs, Investigational; Energy Intake; Fasting; Female; Food-Drug Interactions; Humans; Intestinal Absorption; Male; Middle Aged; Piperazines; Postprandial Period; Psychotic Disorders; Schizophrenia; Thiazoles; Treatment Outcome; Young Adult | 2010 |
Protracted, dose-dependent weight loss after addition of ziprasidone to a stable regimen of clozapine.
Topics: Adult; Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Humans; Piperazines; Schizophrenia; Thiazoles; Time Factors; Weight Loss | 2010 |
A case of schizophrenia with Meige syndrome induced by long-term aripiprazole successfully treated with perospirone.
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Isoindoles; Meige Syndrome; Piperazines; Quinolones; Schizophrenia; Thiazoles; Young Adult | 2011 |
Measurement of the serotonin 1A receptor availability in patients with schizophrenia during treatment with the antipsychotic medication ziprasidone.
Topics: Adult; Antipsychotic Agents; Brain; Carbon Radioisotopes; Female; Humans; Magnetic Resonance Imaging; Male; Piperazines; Positron-Emission Tomography; Psychiatric Status Rating Scales; Pyridines; Radioligand Assay; Receptor, Serotonin, 5-HT1A; Schizophrenia; Serotonin Antagonists; Thiazoles | 2011 |
Effects of risperidone, quetiapine and ziprasidone on ethanol withdrawal syndrome in rats.
Topics: Alcoholism; Animals; Antipsychotic Agents; Behavior, Animal; Body Weight; Central Nervous System Depressants; Comorbidity; Dibenzothiazepines; Ethanol; Humans; Hyperkinesis; Male; Motor Activity; Piperazines; Psychomotor Agitation; Quetiapine Fumarate; Rats; Rats, Wistar; Risperidone; Schizophrenia; Substance Withdrawal Syndrome; Thiazoles; Time Factors | 2011 |
Clinical Global Impression of Improvement (CGI-I) as a valid proxy measure for remission in schizophrenia: analyses of ziprasidone clinical study data.
Topics: Antipsychotic Agents; Follow-Up Studies; Humans; Outcome Assessment, Health Care; Piperazines; Predictive Value of Tests; Proxy; Psychiatric Status Rating Scales; ROC Curve; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Thiazoles | 2011 |
Switching among antipsychotics in everyday clinical practice: focus on ziprasidone.
Topics: Antipsychotic Agents; Drug Substitution; Humans; Patient Education as Topic; Piperazines; Schizophrenia; Thiazoles | 2011 |
What can large simple trials do for psychiatry?
Topics: Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Death, Sudden, Cardiac; Humans; Long QT Syndrome; Multicenter Studies as Topic; Piperazines; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; Risk Factors; Schizophrenia; Thiazoles | 2011 |
Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Dibenzothiazepines; Female; Hospitalization; Hospitals, Psychiatric; Humans; Male; Medication Adherence; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2012 |
Lurasidone (Latuda) for schizophrenia.
Topics: Antipsychotic Agents; Contraindications; Controlled Clinical Trials as Topic; Drug Interactions; Humans; Isoindoles; Lurasidone Hydrochloride; Schizophrenia; Thiazoles | 2011 |
Use of ziprasidone in patients with schizophrenia in four European countries.
Topics: Adult; Antipsychotic Agents; Cross-Sectional Studies; Europe; Female; Health Care Surveys; Humans; Male; Piperazines; Retrospective Studies; Schizophrenia; Thiazoles | 2011 |
Update on newer antipsychotic drugs.
Topics: Adult; Aged; Antipsychotic Agents; Bipolar Disorder; Child; Clinical Trials as Topic; Dibenzocycloheptenes; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Isoindoles; Isoxazoles; Lurasidone Hydrochloride; Male; Piperidines; Pregnancy; Schizophrenia; Thiazoles; Treatment Outcome | 2011 |
Antipsychotic treatment--side-effect and/or metabolic syndrome.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Combined Modality Therapy; Drug Substitution; Female; Humans; Metabolic Syndrome; Olanzapine; Piperazines; Psychotherapy; Schizophrenia; Schizophrenic Psychology; Social Adjustment; Thiazoles; Weight Gain | 2011 |
Assessments of suicidality in double-blind, placebo-controlled trials of ziprasidone.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Child; Confidence Intervals; Humans; Odds Ratio; Piperazines; Randomized Controlled Trials as Topic; Risk; Schizophrenia; Suicidal Ideation; Suicide; Suicide, Attempted; Thiazoles | 2011 |
Question regarding ziprasidone and QTc interval prolongation in the ZODIAC study.
Topics: Adult; Antipsychotic Agents; Female; Humans; Long QT Syndrome; Male; Piperazines; Schizophrenia; Thiazoles; Treatment Outcome | 2011 |
Outcome assessment of an antipsychotic drug algorithm: effects of the Mississippi State Hospital algorithm project.
Topics: Adult; Algorithms; Antipsychotic Agents; Female; Hospitals, State; Humans; Male; Medication Adherence; Mississippi; Piperazines; Psychiatric Status Rating Scales; Quality of Health Care; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2011 |
The novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptor-mediated synaptic responses.
Topics: Animals; Antipsychotic Agents; Clozapine; Cognition Disorders; Disease Models, Animal; Isoindoles; Lurasidone Hydrochloride; Rats; Receptor, Serotonin, 5-HT2A; Receptors, N-Methyl-D-Aspartate; Schizophrenia; Synaptic Transmission; Thiazoles | 2012 |
Pisa syndrome and laryngeal dystonia induced by novel antipsychotics.
Topics: Adult; Antipsychotic Agents; Dystonia; Humans; Imidazoles; Indoles; Laryngeal Diseases; Male; Middle Aged; Piperazines; Risperidone; Schizophrenia; Syndrome; Thiazoles | 2011 |
Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Female; Haloperidol; Humans; Male; Medical Records; Olanzapine; Perphenazine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Sulpiride; Thiazoles; Time Factors; Treatment Outcome | 2011 |
Ziprasidone's effect on metabolic markers in patients with diabetes and chronic schizophrenia.
Topics: Analysis of Variance; Antipsychotic Agents; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Chronic Disease; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Insulin; Lipids; Male; Metabolic Syndrome; Middle Aged; Piperazines; Polypharmacy; Prospective Studies; Psychiatric Status Rating Scales; Schizophrenia; Thiazoles; Treatment Outcome | 2012 |
The impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chi-Square Distribution; Clozapine; Dibenzothiazepines; Humans; Missouri; Olanzapine; Piperazines; Practice Patterns, Physicians'; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2012 |
Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Decision Support Techniques; Economics, Pharmaceutical; Health Services; Humans; Models, Economic; Olanzapine; Piperazines; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recurrence; Schizophrenia; Thiazoles | 2012 |
Improvement in QTc prolongation induced by zotepine following a switch to perospirone.
Topics: Antipsychotic Agents; Dibenzothiepins; Electrocardiography; Female; Haloperidol; Heart Rate; Humans; Isoindoles; Long QT Syndrome; Middle Aged; Schizophrenia; Thiazoles; Water-Electrolyte Imbalance | 2012 |
Serum prolactin levels and the acute-phase efficacy in drug-naïve schizophrenia treated with ziprasidone and olanzapine (translated version).
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Drug Monitoring; Female; Humans; Interview, Psychological; Male; Olanzapine; Pharmacovigilance; Piperazines; Prolactin; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome | 2012 |
Network-assisted investigation of antipsychotic drugs and their targets.
Topics: Antipsychotic Agents; Clopenthixol; Databases, Factual; Drug Interactions; Gene Regulatory Networks; Humans; Piperazines; Schizophrenia; Thiazoles; Thiothixene | 2012 |
State and trait markers of emotionally charged visual event-related potentials (P300) in drug-naïve schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Emotions; Event-Related Potentials, P300; Evoked Potentials, Visual; Facial Expression; Female; Humans; Isoindoles; Male; Olanzapine; Photic Stimulation; Psychomotor Performance; Reaction Time; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles | 2012 |
Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist.
Topics: Animals; Cognition Disorders; Disease Models, Animal; Dopamine D2 Receptor Antagonists; Female; Haloperidol; Isoindoles; Lurasidone Hydrochloride; Phencyclidine; Piperazines; Piperidines; Pyridines; Pyrimidines; Rats; Rats, Long-Evans; Receptors, N-Methyl-D-Aspartate; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT2 Receptor Agonists; Thiazoles; Urea | 2012 |
Effect of 5-HT5A antagonists in animal models of schizophrenia, anxiety and depression.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Anxiety; Biphenyl Compounds; Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Guanidines; Male; Rats; Rats, Wistar; Receptors, Serotonin; Schizophrenia; Serotonin Antagonists; Swimming; Thiazoles; Vocalization, Animal | 2012 |
Inhibition of mouse brown adipocyte differentiation by second-generation antipsychotics.
Topics: Adipocytes, Brown; Adipogenesis; Adipokines; Animals; Antipsychotic Agents; Cell Differentiation; Cell Line; Cell Survival; Clozapine; Dibenzothiazepines; Gene Expression Regulation; Humans; Mice; Piperazines; Quetiapine Fumarate; Schizophrenia; Thiazoles; Weight Gain | 2012 |
Serotonin 1A receptors in the action of antipsychotic drugs: comment on 'Measurement of the serotonin 1A receptor availability in patients with schizophrenia during treatment with the antipsychotic medication ziprasidone' by Frankle et al. 2011; 25(6): 73
Topics: Brain; Female; Humans; Male; Piperazines; Receptor, Serotonin, 5-HT1A; Schizophrenia; Thiazoles | 2012 |
Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: a retrospective cohort study.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Databases, Factual; Dibenzothiazepines; Female; Humans; Male; Medication Adherence; Patient Discharge; Piperazines; Quetiapine Fumarate; Quinolones; Retrospective Studies; Schizophrenia; Thiazoles | 2012 |
A case of catatonia in a 14-year-old girl with schizophrenia treated with electroconvulsive therapy.
Topics: Adolescent; Amantadine; Antiparkinson Agents; Antipsychotic Agents; Benzodiazepines; Catatonia; Combined Modality Therapy; Creatine Kinase; Dibenzothiazepines; Diseases in Twins; Drug Substitution; Drug Therapy, Combination; Electroconvulsive Therapy; Female; Humans; Neurologic Examination; Olanzapine; Piperazines; Quetiapine Fumarate; Recurrence; Schizophrenia; Thiazoles | 2013 |
Priapism associated with two atypical antipsychotic agents.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Humans; Male; Piperazines; Priapism; Risperidone; Schizophrenia; Thiazoles | 2002 |
The value of atypical antipsychotics in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dopamine Antagonists; Drug Labeling; Humans; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Risperidone; Safety; Schizophrenia; Thiazoles; United States | 2002 |
Prolonged erections associated with ziprasidone treatment: a case report.
Topics: Adult; Antipsychotic Agents; Humans; Male; Penile Erection; Piperazines; Priapism; Schizophrenia; Thiazoles | 2003 |
Mania associated with initiation of ziprasidone.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Drug Administration Schedule; Humans; Male; Piperazines; Schizophrenia; Thiazoles | 2003 |
[Treatment of young people with atypical antipsychotic agents].
Topics: Adolescent; Antipsychotic Agents; Humans; Piperazines; Schizophrenia; Thiazoles | 2003 |
Possible ziprasidone-induced mania.
Topics: Adolescent; Antipsychotic Agents; Bipolar Disorder; Female; Humans; Piperazines; Schizophrenia; Thiazoles | 2003 |
Schizophrenia, VI: Treatments.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Perphenazine; Piperazines; Pirenzepine; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2003 |
Ziprasidone-induced Pisa syndrome after clozapine treatment.
Topics: Clozapine; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Piperazines; Schizophrenia; Serotonin Antagonists; Thiazoles | 2003 |
[Perospirone therapy in elderly patients with schizophrenia].
Topics: Aged; Antipsychotic Agents; Female; Humans; Indoles; Isoindoles; Male; Schizophrenia; Thiazoles | 2003 |
Similarities and differences among antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Haloperidol; Humans; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2003 |
Introduction. Ziprasidone in schizophrenia: from acute treatment to long-term management.
Topics: Acute Disease; Antipsychotic Agents; Chronic Disease; Clinical Trials as Topic; Humans; Long-Term Care; Piperazines; Schizophrenia; Schizophrenic Psychology; Serotonin Antagonists; Thiazoles | 2003 |
Ziprasidone and cognition: the evolving story.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Cognition Disorders; Dose-Response Relationship, Drug; Humans; Neuropsychological Tests; Piperazines; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Serotonin Antagonists; Thiazoles; Treatment Outcome | 2003 |
Two cases of perospirone-induced mania in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Female; Humans; Indoles; Isoindoles; Male; Schizophrenia; Thiazoles | 2004 |
Use of perospirone for obesity and diabetes mellitus in patients with schizophrenia: three case reports.
Topics: Adult; Antipsychotic Agents; Diabetes Mellitus, Type 2; Humans; Indoles; Isoindoles; Male; Middle Aged; Obesity; Schizophrenia; Thiazoles; Weight Gain | 2004 |
Improvement in prosocial functioning after a switch to ziprasidone treatment.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Schizophrenia; Thiazoles | 2004 |
Combination of ziprasidone and clozapine in treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Resistance; Drug Therapy, Combination; Female; Humans; Piperazines; Schizophrenia; Thiazoles; Treatment Outcome | 2004 |
Effects of acute treatment with antidepressant drugs on sensorimotor gating deficits in rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Antipsychotic Agents; Bupropion; Citalopram; Desipramine; Dextroamphetamine; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Male; Norepinephrine; Piperazines; Rats; Rats, Wistar; Reflex, Startle; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Thiazoles | 2005 |
Atypical antipsychotics: matching receptor profile to individual patient's clinical profile.
Topics: Adult; Affect; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Cognition; Dibenzothiazepines; Dose-Response Relationship, Drug; Histamine; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Receptors, Muscarinic; Receptors, Serotonin; Risperidone; Schizophrenia; Thiazoles | 2004 |
Ziprasidone: first year experience in a hospital setting.
Topics: Adult; Antipsychotic Agents; Depressive Disorder; Electrocardiography; Female; Hospitalization; Humans; Inpatients; Length of Stay; Long QT Syndrome; Male; Middle Aged; Mood Disorders; Piperazines; Retrospective Studies; Schizophrenia; Thiazoles; Treatment Outcome | 2004 |
Tardive dyskinesia in 2 patients treated with ziprasidone.
Topics: Adult; Antipsychotic Agents; Delusions; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Follow-Up Studies; Hallucinations; Humans; Long-Term Care; Male; Neurologic Examination; Piperazines; Psychiatric Status Rating Scales; Recurrence; Schizophrenia; Thiazoles | 2004 |
[Treatment of "the premonitory state of schizophrenia" with atypical antipsychotics].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Indoles; Isoindoles; Male; Middle Aged; Olanzapine; Risperidone; Schizophrenia; Thiazoles | 2004 |
Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Electrocardiography; Female; Glycated Hemoglobin; Heart Rate; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Olanzapine; Piperazines; Retrospective Studies; Schizophrenia; Thiazoles; Triglycerides | 2005 |
Automated determination of ziprasidone by HPLC with column switching and spectrophotometric detection.
Topics: Adult; Automation; Benzodiazepines; Chromatography, High Pressure Liquid; Clozapine; Drug Administration Schedule; Drug Monitoring; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Reproducibility of Results; Schizophrenia; Sensitivity and Specificity; Spectrophotometry; Thiazoles; Time Factors | 2005 |
Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation.
Topics: Aminopyridines; Animals; Antipsychotic Agents; Aripiprazole; Clozapine; Corpus Striatum; Disease Models, Animal; Excitatory Amino Acid Agonists; Haloperidol; Kainic Acid; Male; Mice; Mice, Inbred C57BL; Piperazines; Piperidines; Pyridines; Quinolones; Receptor, Serotonin, 5-HT1A; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Thiazoles | 2005 |
An African patient with ziprasidone intolerance.
Topics: Africa; Antipsychotic Agents; Aripiprazole; Dystonia; Ethnicity; Germany; Humans; Male; Middle Aged; Pharmacogenetics; Piperazines; Quinolones; Schizophrenia; Thiazoles; Treatment Outcome | 2005 |
Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Controlled Clinical Trials as Topic; Dibenzothiazepines; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Risperidone; Schizophrenia; Thiazoles | 2005 |
Methodological concerns in a trial of ziprasidone and olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Bias; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Industry; Humans; Olanzapine; Piperazines; Product Labeling; Randomized Controlled Trials as Topic; Research Design; Research Support as Topic; Schizophrenia; Thiazoles | 2005 |
Methodological concerns in a trial of ziprasidone and olanzapine.
Topics: Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Bias; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Lorazepam; Olanzapine; Piperazines; Randomized Controlled Trials as Topic; Research Design; Schizophrenia; Schizophrenic Psychology; Thiazoles | 2005 |
Ziprasidone-induced hypersensitivity syndrome in an aged schizophrenia patient.
Topics: Aged; Antipsychotic Agents; Drug Hypersensitivity; Female; Humans; Piperazines; Schizophrenia; Thiazoles; Treatment Outcome | 2005 |
Atypical antipsychotic drugs and organization of long-term semantic memory: multidimensional scaling and cluster analyses of category fluency performance in schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cluster Analysis; Female; Humans; Male; Memory; Olanzapine; Piperazines; Quality of Life; Reading; Schizophrenia; Schizophrenic Psychology; Semantics; Thiazoles | 2006 |
Urinary hesitancy and retention caused by ziprasidone.
Topics: Adult; Antipsychotic Agents; Humans; Male; Piperazines; Schizophrenia; Thiazoles; Urinary Retention | 2006 |
From clinical research to clinical practice: a 4-year review of ziprasidone.
Topics: Antipsychotic Agents; Controlled Clinical Trials as Topic; Dopamine Antagonists; Humans; Mood Disorders; Piperazines; Psychotic Disorders; Schizophrenia; Serotonin Antagonists; Thiazoles; Treatment Outcome | 2005 |
Patient- and facility-level factors associated with diffusion of a new antipsychotic in the VA health system.
Topics: Aged; Algorithms; Antipsychotic Agents; Drug Approval; Drug Therapy; Drug Utilization Review; Female; Humans; International Classification of Diseases; Male; Mental Health Services; Middle Aged; Piperazines; Registries; Schizophrenia; Thiazoles; United States; United States Department of Veterans Affairs; Veterans | 2006 |
Interpreting the results of the CATIE study.
Topics: Antipsychotic Agents; Dibenzothiazepines; Humans; National Institute of Mental Health (U.S.); Perphenazine; Piperazines; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome; United States | 2006 |
Interpreting the results of the CATIE study.
Topics: Antipsychotic Agents; Dibenzothiazepines; Humans; Perphenazine; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2006 |
Interpreting the results of the CATIE study.
Topics: Antipsychotic Agents; Dibenzothiazepines; Humans; Perphenazine; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2006 |
Antipsychotic drugs and schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Humans; Olanzapine; Patient Compliance; Perphenazine; Piperazines; Quetiapine Fumarate; Schizophrenia; Thiazoles | 2006 |
Methodological issues in a comparative study of ziprasidone and risperidone.
Topics: Antipsychotic Agents; Drug Administration Schedule; Humans; Piperazines; Randomized Controlled Trials as Topic; Research Design; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2006 |
Prescribing behavior and marketing practices.
Topics: Aged; Antipsychotic Agents; Drug Industry; Drug Therapy; Female; Humans; Male; Marketing; Mental Health Services; Middle Aged; Piperazines; Practice Patterns, Physicians'; Registries; Schizophrenia; Thiazoles; United States; United States Department of Veterans Affairs; Veterans | 2006 |
Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study.
Topics: Antipsychotic Agents; Comorbidity; Conduct Disorder; Cross-Sectional Studies; Diagnosis, Dual (Psychiatry); Double-Blind Method; Female; Humans; Male; Multicenter Studies as Topic; Piperazines; Prevalence; Randomized Controlled Trials as Topic; Risk Factors; Schizophrenia; Schizophrenic Psychology; Sex Factors; Substance-Related Disorders; Thiazoles; Treatment Outcome; United States | 2006 |
Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.
Topics: Antipsychotic Agents; Benzodiazepines; Computer Simulation; Cost of Illness; Cost-Benefit Analysis; Dibenzothiazepines; Drug Costs; Haloperidol; Health Care Costs; Humans; Models, Econometric; Olanzapine; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Thailand; Thiazoles; Treatment Outcome | 2005 |
Ziprasidone-associated pedal edema in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Diuretics; Drug Hypersensitivity; Edema; Female; Foot Diseases; Humans; Immunoglobulin E; Middle Aged; Piperazines; Schizophrenia; Thiazoles | 2006 |
Injectable atypical antipsychotics for agitation in borderline personality disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Disorder; Comorbidity; Emergency Services, Psychiatric; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Schizophrenia; Thiazoles; Treatment Outcome | 2006 |
The dimensions of clinical and cognitive change in schizophrenia: evidence for independence of improvements.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Cognition Disorders; Female; Humans; Male; Middle Aged; Piperazines; Schizophrenia; Schizophrenic Psychology; Thiazoles | 2006 |
A patient using ziprasidone with polydipsia, seizure, hyponatremia and rhabdomyolysis.
Topics: Adult; Antipsychotic Agents; Drinking Behavior; Humans; Hyponatremia; Male; Piperazines; Rhabdomyolysis; Schizophrenia; Seizures; Thiazoles | 2006 |
Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Binding, Competitive; Biogenic Monoamines; CHO Cells; Clozapine; Cricetinae; Dibenzothiazepines; Dopamine; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Receptors, Dopamine; Receptors, Serotonin; Schizophrenia; Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Serotonin Receptor Agonists; Synaptic Transmission; Thiazoles | 2006 |
A model of anticholinergic activity of atypical antipsychotic medications.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Binding Sites; Clozapine; Cognition Disorders; Dibenzothiazepines; Dose-Response Relationship, Drug; Female; Humans; Male; Neuropsychological Tests; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Receptors, Cholinergic; Risperidone; Schizophrenia; Thiazoles | 2006 |
Probable association between ziprasidone and worsening hypertension.
Topics: Antipsychotic Agents; Female; Humans; Hypertension; Middle Aged; Piperazines; Schizophrenia; Thiazoles | 2006 |
Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Drug Administration Schedule; Drug Prescriptions; Female; Humans; International Classification of Diseases; Male; Olanzapine; Patient Compliance; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Time Factors | 2006 |
Does antipsychotic polypharmacy increase the risk for metabolic syndrome?
Topics: Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Mass Index; Cholesterol, HDL; Clozapine; Cross-Sectional Studies; Dibenzothiazepines; Drug Therapy, Combination; Female; Humans; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Piperazines; Quetiapine Fumarate; Quinolones; Risk Factors; Schizophrenia; Thiazoles; Triglycerides | 2007 |
Determination of ziprasidone in human plasma by liquid chromatography-electrospray tandem mass spectrometry and its application to plasma level determination in schizophrenia patients.
Topics: Adult; Aged; Chromatography, Liquid; Female; Humans; Male; Middle Aged; Molecular Structure; Piperazines; Reproducibility of Results; Schizophrenia; Tandem Mass Spectrometry; Thiazoles | 2007 |
High-dose ziprasidone-induced acute dystonia.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Dystonia; Female; Humans; Piperazines; Schizophrenia; Thiazoles | 2007 |
Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Weight; Cholesterol; Female; Humans; Male; Metabolic Diseases; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Retrospective Studies; Schizophrenia; Severity of Illness Index; Statistics, Nonparametric; Thiazoles; Time Factors | 2007 |
Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: results of a multi-centre observational trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Austria; Blood Glucose; Body Weight; Brief Psychiatric Rating Scale; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Germany; Humans; Lipids; Male; Middle Aged; Patient Dropouts; Piperazines; Product Surveillance, Postmarketing; Prospective Studies; Psychotic Disorders; Quality of Life; Schizophrenia; Thiazoles; Treatment Outcome | 2007 |
Cost-effectiveness analysis of schizophrenia relapse prevention : an economic evaluation of the ZEUS (Ziprasidone-Extended-Use-In-Schizophrenia) study in Spain.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Models, Econometric; Piperazines; Program Evaluation; Recurrence; Reproducibility of Results; Schizophrenia; Spain; Thiazoles; Time Factors | 2006 |
Alteration in serum neural cell adhesion molecule in patients of schizophrenia.
Topics: Adult; Age Factors; Antipsychotic Agents; Benzodiazepines; Blotting, Western; Chronic Disease; Dibenzothiazepines; Female; Humans; Indoles; Isoindoles; Male; Middle Aged; Molecular Weight; Neural Cell Adhesion Molecules; Olanzapine; Protein Isoforms; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles | 2007 |
New-onset diabetic ketoacidosis induced by the addition of perospirone hydrochloride in a patient treated with risperidone.
Topics: Adult; Diabetic Ketoacidosis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Humans; Indoles; Isoindoles; Male; Risk Assessment; Risperidone; Schizophrenia; Severity of Illness Index; Thiazoles; Treatment Outcome | 2007 |
[Pharmacokinetics of perospirone hydrochloride at an excessive dose and changes in the serum prolactin level].
Topics: Adult; Antipsychotic Agents; Chromatography, High Pressure Liquid; Consciousness Disorders; Enzyme-Linked Immunosorbent Assay; Female; Humans; Indoles; Isoindoles; Prolactin; Schizophrenia; Thiazoles; Time Factors | 2007 |
Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment.
Topics: Adult; Antipsychotic Agents; Biperiden; Diagnosis, Differential; Diazepam; Drug Therapy, Combination; Humans; Infusions, Intravenous; Male; Neuroleptic Malignant Syndrome; Neurologic Examination; Parkinsonian Disorders; Piperazines; Schizophrenia; Thiazoles | 2007 |
Effective adjunctive use of tandospirone with perospirone for enhancing verbal memory and quality of life in schizophrenia.
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Follow-Up Studies; Humans; Indoles; Isoindoles; Male; Memory; Piperazines; Pyrimidines; Quality of Life; Schizophrenia; Schizophrenic Psychology; Thiazoles; Verbal Behavior | 2007 |
Comments on the report of neuroleptic malignant syndrome induced by ziprasidone.
Topics: Antipsychotic Agents; Benzodiazepines; Diagnosis, Differential; Humans; Male; Neuroleptic Malignant Syndrome; Olanzapine; Patient Compliance; Patient Discharge; Piperazines; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome | 2007 |
The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Humans; Middle Aged; Neuropsychological Tests; Olanzapine; Piperazines; Remission Induction; Risperidone; Schizophrenia; Thiazoles | 2007 |
Impairment in error monitoring predicts poor executive function in schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Cognition Disorders; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Male; Memory, Short-Term; Neuropsychological Tests; Olanzapine; Piperazines; Reaction Time; Risperidone; Schizophrenia; Self Efficacy; Severity of Illness Index; Thiazoles | 2007 |
Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Female; Follow-Up Studies; Humans; Male; Middle Aged; Patient Readmission; Piperazines; Proportional Hazards Models; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risk Factors; Risperidone; Schizophrenia; Schizophrenia, Paranoid; Schizophrenic Psychology; Sensitivity and Specificity; Substance Withdrawal Syndrome; Survival Rate; Thiazoles | 2008 |
The effectiveness of ziprasidone in treating impaired quality of life in schizophrenia: a 12-month, open-label, flexible-dose, naturalistic observational study of patients undergoing usual care.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Chronic Disease; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quality of Life; Schizophrenia; Schizophrenic Psychology; Surveys and Questionnaires; Thiazoles | 2007 |
Acute urinary retention associated with selective serotonin reuptake inhibitors and ziprasidone.
Topics: Acute Disease; Antipsychotic Agents; Depressive Disorder, Major; Drug Monitoring; Electroconvulsive Therapy; Humans; Male; Middle Aged; Piperazines; Receptors, Serotonin, 5-HT2; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Serotonin Plasma Membrane Transport Proteins; Thiazoles; Urinary Catheterization; Urinary Retention | 2007 |
Show me the evidence: using number needed to treat.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Confidence Intervals; Data Interpretation, Statistical; Decision Making; Evidence-Based Medicine; Humans; Likelihood Functions; Olanzapine; Piperazines; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2007 |
Long-term perospirone treatment with a single dose at bedtime in schizophrenia: relevant to intermittent dopamine D2 receptor antagonism.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Chromatography, High Pressure Liquid; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Indoles; Isoindoles; Longitudinal Studies; Male; Middle Aged; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Thiazoles; Treatment Outcome | 2008 |
Efficacy of antipsychotics to reverse phencyclidine-induced social interaction deficits in female rats--a preliminary investigation.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Disease Models, Animal; Drug Interactions; Excitatory Amino Acid Antagonists; Female; Haloperidol; Matched-Pair Analysis; Phencyclidine; Piperazines; Rats; Rats, Inbred Strains; Schizophrenia; Schizophrenic Psychology; Social Behavior; Social Behavior Disorders; Thiazoles | 2008 |
A case report with ziprasidone-induced catatonic symptoms.
Topics: Adult; Antipsychotic Agents; Catatonia; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Schizophrenia; Thiazoles | 2007 |
Did CATIE influence antipsychotic use?
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Therapy; Haloperidol; Humans; Olanzapine; Perphenazine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles | 2008 |
Rat brain binding sites for pramipexole, a clinically useful D3-preferring dopamine agonist.
Topics: Animals; Autoradiography; Benzothiazoles; Binding Sites; Brain; Cloning, Molecular; Dopamine Agonists; Male; Parkinson Disease; Pramipexole; Rats; Rats, Sprague-Dawley; Schizophrenia; Tetrahydronaphthalenes; Thiazoles | 1995 |
1192U90 in animal tests that predict antipsychotic efficacy, anxiolysis, and extrapyramidal side effects.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Columbidae; Male; Mice; Piperazines; Rats; Rats, Wistar; Schizophrenia; Thiazoles | 1996 |
The distribution of body mass index among individuals with and without schizophrenia.
Topics: Antipsychotic Agents; Body Mass Index; Clinical Trials as Topic; Comorbidity; Female; Health Surveys; Humans; Male; Obesity; Piperazines; Schizophrenia; Sex Factors; Thiazoles; United States; Weight Gain | 1999 |
In vivo receptor occupancy of NRA0045, a putative atypical antipsychotic, in rats.
Topics: Animals; Antipsychotic Agents; Binding, Competitive; Cerebral Cortex; Clozapine; Corpus Striatum; Dopamine Antagonists; Haloperidol; Male; Nucleus Accumbens; Pyrrolidines; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT2A; Receptors, Adrenergic, alpha-1; Receptors, Dopamine; Receptors, Serotonin; Risperidone; Schizophrenia; Thiazoles | 1999 |
[Therapy of schizophrenia with high compliance. Ziprasidon increases pharmaceutical options].
Topics: Antipsychotic Agents; Hospitalization; Humans; Piperazines; Schizophrenia; Thiazoles | 1999 |
Quality of life and new antipsychotics in schizophrenia. Are patients better off?
Topics: Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Humans; Olanzapine; Patient Compliance; Patient Satisfaction; Piperazines; Pirenzepine; Quality of Life; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles | 1999 |
Novel antipsychotic use in schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Dibenzothiepins; Drug Administration Schedule; Humans; Olanzapine; Piperazines; Pirenzepine; Practice Patterns, Physicians'; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2000 |
Ziprasidone hydrochloride approved for treatment of schizophrenia, but with major warning.
Topics: Antipsychotic Agents; Drug Labeling; Humans; Piperazines; Randomized Controlled Trials as Topic; Schizophrenia; Thiazoles | 2001 |
Ziprasidone (Geodon) for schizophrenia.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Dopamine Antagonists; Humans; Intestinal Absorption; Piperazines; Schizophrenia; Serotonin Antagonists; Thiazoles | 2001 |
Ziprasidone approved.
Topics: Antipsychotic Agents; Drug Approval; Humans; Piperazines; Schizophrenia; Thiazoles | 2001 |
Ziprasidone hydrochloride.
Topics: Antipsychotic Agents; Drug Interactions; Female; Humans; Male; Piperazines; Pregnancy; Schizophrenia; Thiazoles | 2002 |
[Exercising caution in choice of psychotropic drugs. Avoid drug-induced weight gain].
Topics: Antipsychotic Agents; Clinical Trials as Topic; Humans; Piperazines; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome; Weight Gain | 2002 |
3-[4-[1-(6-Fluorobenzo[b]thiophen-3-yl)-4-piperazinyl]butyl]- 2,5,5-trimethyl-4-thiazolidinone: a new atypical antipsychotic agent for the treatment of schizophrenia.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Mice; Rats; Receptors, Dopamine; Receptors, Serotonin; Schizophrenia; Substrate Specificity; Tetrahydronaphthalenes; Thiazoles; Thiazolidines | 1992 |